METHOD AND REAGENT FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR

Abstract: Nucleic acid molecule which modulates the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor.

Description: DESCRIPTION Method and Reagent for the Treatment of Diseases or Conditions Related to Levels of Vascular Endothelial Growth Factor Receptor Background Of The Invention This application is a continuation-in-part of Pavco et al., U.S. Serial No. 60/005,974 all of which is hereby incorporated by reference herein (including drawings) . This invention relates to methods and reagents for the treatment of diseases or conditions relating to the levels of expression of vascular endothelial growth factor (VEGF) receptor(s) . The following is a discussion of relevant art, none of which is admitted to be prior art to the present invention. VEGF, also referred to as vascular permeability factor (VPF) and vasculotropin, is a potent and highly specific mitogen of vascular endothelial cells (for a review see Ferrara, 1993 Trends Cardiovas . Med. 3, 244; Neufeld et al . , 1994 Prog. Growth Factor Res . 5, 89) . VEGF induced neovascularization is implicated in various pathological conditions such as tumor angiogenesis, proliferative diabetic retinopathy, hypoxia-induced angiogenesis, rheumatoid arthritis, psoriasis, wound healing and others. VEGF, an endothelial cell-specific mitogen, is a 34-45 kDa glycoprotein with a wide range of activities that include promotion of angiogenesis, enhancement of vascular-permeability and others. VEGF belongs to the platelet-derived growth factor (PDGF) family of growth factors with approximately 18% homology with the A and B chain of PDGF at the amino acid level. Additionally, VEGF contains the eight conserved cysteine residues common to all growth factors belonging to the PDGF family (Neufeld et al . , supra) . VEGF protein is believed to exist predominantly as disulfide-linked homodimers; monomers of VEGF have been shown to be inactive (Plouet et al . , 1989 E BO J. 8, 3801) . VEGF exerts its influence on vascular endothelial cells by binding to specific high-affinity cell surface receptors. Covalent cross-linking experiments with 125 I-labeled VEGF protein have led to the identification of three high molecular weight complexes of 225, 195 and 175 kDa presumed to be VEGF and VEGF receptor complexes (Vais an et al . , 1990 J. Biol . Chem. 265, 19461) . Based on these studies VEGF-specific receptors of 180, 150 and 130 kDa molecular mass were predicted. In endothelial cells, receptors of 150 and the 130 kDa have been identi¬ fied. The VEGF receptors belong to the superfamily of receptor tyrosine kinases (RTKs) characterized by a conserved cytoplasmic catalytic kinase domain and a hydrophylic kinase sequence. The extracellular domains of the VEGF receptors consist of seven immunoglobulin-like domains that are thought to be involved in VEGF binding functions. The two most abundant and high-affinity receptors of VEGF are flt-1 ( f s-like tyrosine kinase) cloned by Shibuya et al . , 1990 Oncogene 5, 519 and KDR (kinase- insert-domain-containing receptor) cloned by Terman et al . , 1991 Oncogene 6, 1677. The murine homolog of KDR, cloned by Mathews et al . , 1991, Proc . Natl . Acad . Sci . , USA, 88, 9026, shares 85% amino acid homology with KDR and is termed as flk-1 (fetal liver kinase-1) . Recently it has been shown that the high-affinity binding of VEGF to its receptors is modulated by cell surface-associated heparin and heparin-like molecules (Gitay-Goren et al . , 1992 J. Biol . Chem . 261 , 6093) . VEGF expression has been associated with several pathological states such as tumor angiogenesis, several forms of blindness, rheumatoid arthritis, psoriasis and others. Following is a brief summary of evidence supporting the involvement of VEGF in various diseases: 1) Tumor angiogenesis: Increased levels of VEGF gene expression have been reported in vascularized and edema- associated brain tumors (Berkman et al . , 1993 J. Clini . Invest . 91, 153) . A more direct demostration of the role of VEGF in tumor angiogenesis was demonstrated by Jim Kim et al . , 1993 Nature 362,841 wherein, monoclonal antibodies against VEGF were successfully used to inhibit the growth of rhabdomyosarcoma, glioblastoma multiforme cells in nude mice. Similarly, expression of a dominant negative mutated form of the flt-1 VEGF receptor inhibits vascular- ization induced by human glioblastoma cells in nude mice (Millauer et al . , 1994, Nature 367, 576) . 2) Ocular diseses: Aiello et al . , 1994 New Engl . J. Med. 331, 1480, showed that the ocular fluid, of a major- ity of patients suffering from diabetic retinopathy and other retinal disorders, contains a high concentration of VEGF. Miller et al . , 1994 Am. J. Pathol . 145, 574, reported elevated levels of VEGF mRΝA in patients suffer¬ ing from retinal ischemia. These observations support a direct role for VEGF in ocular diseases. 3) Psoriasis: Detmar et al . , 1994 J. Exp. Med. 180, 1141 reported that VEGF and its receptors were over- expressed in psoriatic skin and psoriatic dermal micro- vessels, suggesting that VEGF plays a significant role in psoriasis. 4) Rheumatoid arthritis: Immunohistochemistry and in si tu hybridization studies on tissues from the joints of patients suffering from rheumatoid arthritis show an increased level of VEGF and its receptors (Fava et al . , 1994 J. Exp. Med . 180, 341) . Additionally, Koch et al . , 1994 J " . Immunol . 152, 4149, found that VEGF-specific antibodies were able to significantly reduce the mitogenic activity of synovial tissues from patients suffering from rheumatoid arthritis. These observations support a direct role for VEGF in rheumatoid arthritis. In addition to the above data on pathological conditions involving excessive angiogenesis, a number of studies have demonstrated that VEGF is both necessary and sufficient for neovascularization. Takashita et al . , 1995 J. Clin . Invest . 93, 662, demonstrated that a single injection of VEGF augmented collateral vessel development in a rabbit model of ischemia. VEGF also can induce neo¬ vascularization when injected into the cornea. Expression of the VEGF gene in CHO cells is sufficient to confer tumorigenic potential to the cells. Kim et al . , supra and Millauer et al . , supra used monoclonal antibodies against VEGF or a dominant negative form of flk-1 receptor to inhibit tumor-induced neovascularization. During development, VEGF and its receptors are associated with regions of new vascular growth (Millauer et al . , 1993 Cell 72, 835; Shalaby et al . , 1993 J. Clin . Invest . 91, 2235) . Furthermore, transgenic mice lacking either of the VEGF receptors are defective in blood vessel formation, infact these mouse do not survive; flk-1 appears to be required for differentiation of endothelial cells, while flt-1 appears to be required at later stages of vessel formation (Shalaby et al . , 1995 Nature 376, 62; Fung et al . , 1995 Nature 376, 66) . Thus, these receptors must be present to properly signal endothelial cells or their precursors to respond to vascularization-promoting stimuli. All of the conditions listed above, involve extensive vascularization. This hyper-stimulation of endothelial cells may be alleviated by VEGF antagonists. Thus most of the therapeutic efforts for the above conditions have concentrated on finding inhibitors of the VEGF protein. Kim et al . , 1993 Nature 362, 841 have been successful in inhibiting VEGF-induced tumor growth and angiogenesis in nude mice by treating the mice with VEGF-specific monoclonal antibody. Koch et al . , 1994 J. Immunol . 152, 4149 showed that the mitogenic activity of microvascular endothelial cells found in rheumatoid arthritis (RA) synovial tissue explants and the chemotactic property of endothelial cells from RA synovial fluid can be neutralized significantly by treatment with VEGF-specific antibodies. Ullrich et al . , International PCT Publication No. WO 94/11499 and Millauer et al . , 1994 Nature 367, 576 used a soluble form of flk-1 receptor (dominant-negative mutant) to prevent VEGF-mediated tumor angiogenesis in immuno- deficient mice. Kendall and Thomas, International PCT Publication o. WO 94/21679 describe the use of naturally occuring or recombinantly-engineered soluble forms of VEGF receptors to inhibit VEGF activity. Robinson, International PCT Publication No. WO 95/04142 describes the use of antisense oligonucleotides targeted against VEGF RNA to inhibit VEGF expression. Jellinek et al . , 1994 Biochemistry 33, 10450 describe the use of VEGF-specific high-affinity RNA aptamers to inhibit the binding of VEGF to its receptors. Rockwell and Goldstein, International PCT Publication No. WO 95/21868, describe the use of anti-VEGF receptor monoclonal antibodies to neutralize the the effect of VEGF on endothelial cells. Summary Of The Invention The invention features novel nucleic acid-based techniques [e.g., enzymatic nucleic acid molecules (ribozymes) , antisense nucleic acids, 2-5A antisense chimeras, triplex DNA, antisense nucleic acids containing RNA cleaving chemical groups (Cook et al . , U.S. Patent 5,359,051)] and methods for their use to down regulate or inhibit the expression of receptors of VEGF (VEGF-R) . In a preferred embodiment, the invention features use of one or more of the nucleic acid-based techniques to in¬ hibit the expression of flt-1 and/or flk-1/KDR receptors. By "inhibit" it is meant that the activity of VEGF-R or level of mRNAs or equivalent RNAs encoding VEGF-R is reduced below that observed in the absence of the nucleic acid. In one embodiment, inhibition with ribozymes preferably is below that level observed in the presence of an enzymatically inactive RNA molecule that is able to bind to the same site on the mRNA, but is unable to cleave that RNA. In another embodiment, inhibition with anti- sense oligonucleotides is preferably below that level observed in the presence of for example, an oligonucleo- tide with scrambled sequence or with mismatches. By "enzymatic nucleic acid molecule" it is meant an RNA molecule which has complementarity in a substrate binding region to a specified gene target, and also has an enzymatic activity which is active to specifically cleave target RNA. That is, the enzymatic RNA molecule is able to inter olecularly cleave RNA and thereby inactivate a target RNA molecule. This complementary regions allow sufficient hybridization of the enzymatic RNA molecule to the target RNA and thus permit cleavage. One hundred percent complementarity is preferred, but complementarity as low as 50-75% may also be useful in this invention. By "equivalent" RNA to VEGF-R is meant to include those naturally occurring RNA molecules in various animals, including human, mice, rats, rabbits, primates and pigs. By "antisense nucleic acid" it is meant a non- enzymatic nucleic acid molecule that binds to target RNA by means of RNA-RNA or RNA-DNA or RNA-PNA (protein nucleic acid; Egholm et al . , 1993 Nature 365, 566) interactions and alters the activity of the target RΝA (for a review see Stein and Cheng, 1993 Science 261, 1004) . By "2-5A antisense chimera" it is meant, an antisense oligonucleotide containing a 5' phosphorylated 2' -5'- linked adenylate residues. These chimeras bind to target RΝA in a sequence-specific manner and activate a cellular 2-5A-dependent ribonuclease which, in turn, cleaves the target RΝA (Torrence et al . , 1993 Proc. Natl . Acad. Sci . USA 90, 1300) . By "triplex DΝA" it is meant an oligonucleotide that can bind to a double-stranded DΝA in a sequence-specific manner to form a triple-strand helix. Formation of such triple helix structure has been shown to inhibit tran¬ scription of the targeted gene (Duval-Valentin et al . , 1992 Proc . Natl . Acad . Sci . USA 89, 504) . By "gene" it is meant a nucleic acid that encodes an RNA. By "complementarity" it is meant a nucleic acid that can form hydrogen bond(s) with other RNA sequence by either traditional Watson-Crick or other non-traditional types (for example, Hoogsteen type) of base-paired interactions. Six basic varieties of naturally-occurring enzymatic RNAs are known presently. Each can catalyze the hydro¬ lysis of RNA phosphodiester bonds in trans (and thus can cleave other RNA molecules) under physiological condi- tions. Table I summarizes some of the characteristics of these ribozymes. In general, enzymatic nucleic acids act by first binding to a target RNA. Such binding occurs through the target binding portion of a enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target RNA. Thus, the enzymatic nucleic acid first recognizes and then binds a target RNA through complementary base- pairing, and once bound to the correct site, acts enzymatically to cut the target RNA. Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. After an enzymatic nucleic acid has bound and cleaved its RNA target, it is released from that RNA to search for another target and can repeatedly bind and cleave new targets. Thus, a single ribozyme molecule is able to cleave many molecules of target RNA. In addition, the ribozyme is a highly specific inhibitor of gene expression, with the specific¬ ity of inhibition depending not only on the base-pairing mechanism of binding to the target RNA, but also on the mechanism of target RNA cleavage. Single mismatches, or base-substitutions, near the site of cleavage can completely eliminate catalytic activity of a ribozyme. Ribozymes that cleave the specified sites in VEGF-R mRNAs represent a novel therapeutic approach to treat tumor angiogenesis, ocular diseases, rhuematoid arthritis, psoriasis and others. Applicant indicates that ribozymes are able to inhibit the activity of VEGF-R (specifically flt-1 and flk-1/KDR) and that the catalytic activity of the ribozymes is required for their inhibitory effect. Those of ordinary skill in the art will find that it is clear from the examples described that other ribozymes that cleave VEGF-R mRNAs may be readily designed and are within the invention. In preferred embodiments of this invention, the enzymatic nucleic acid molecule is formed in a hammerhead or hairpin motif, but may also be formed in the motif of a hepatitis delta virus, group I intron or RNaseP RNA (in association with an RNA guide sequence) or Neurospora VS RNA. Examples of such hammerhead motifs are described by Rossi et al . , 1992, AIDS Research and Human Retroviruses 8, 183, of hairpin motifs by Hampel et al . , EP0360257, Hampel and Tritz, 1989 Biochemistry 28, 4929, and Hampel et al . , 1990 Nucleic Acids Res . 18, 299, and an example of the hepatitis delta virus motif is described by Perrotta and Been, 1992 Biochemistry 31, 16; of the RNaseP motif by Guerrier-Takada et al . , 1983 Cell 35, 849, Neurospora VS RNA ribozyme motif is described by Collins (Saville and Collins, 1990 Cell 61, 685-696; Saville and Collins, 1991 Proc . Natl . Acad . Sci . USA 88, 8826-8830; Collins and Olive, 1993 Biochemistry 32, 2795-2799) and of the Group I intron by Cech et al . , U.S. Patent 4,987,071. These specific motifs are not limiting in the invention and those skilled in the art will recognize that all that is important in an enzymatic nucleic acid molecule of this invention is that it has a specific substrate binding site which is complementary to one or more of the target gene RNA regions, and that it have nucleotide sequences within or surrounding that substrate binding site which impart an RNA cleaving activity to the molecule. In a preferred embodiment the invention provides a method for producing a class of enzymatic cleaving agents which exhibit a high degree of specificity for the RNA of a desired target. The enzymatic nucleic acid molecule is preferably targeted to a highly conserved sequence region of target mRNAs encoding VEGF-R proteins (specifically flt-1 and flk-1/KDR) such that specific treatment of a disease or condition can be provided with either one or several enzymatic nucleic acids. Such enzymatic nucleic acid molecules can be delivered exogenously to specific tissue or cellular targets as required. Alternatively, the ribozymes can be expressed from DNA and/or RNA vectors that are delivered to specific cells. Synthesis of nucleic acids greater than 100 nucleo- tides in length is difficult using automated methods, and the therapeutic cost of such molecules is prohibitive. In this invention, small nucleic acid motifs ( e . g. , antisense oligonucleotides, hammerhead or the hairpin ribozymes) are used for exogenous delivery. The simple structure of these molecules increases the ability of the nucleic acid to invade targeted regions of the mRNA structure. However, these nucleic acid molecules can also be expressed within cells from eukaryotic promoters (e.g., Izant and Weintraub, 1985 Science 229, 345; McGarry and Lindquist, 1986 Proc . Natl . Acad. Sci . USA 83, 399; Sullenger-Scanlon et al . , 1991, Proc . Natl . Acad. Sci . USA, 88, 10591-5; Kashani-Sabet et al . , 1992 Antisense Res . Dev. , 2, 3-15; Dropulic et al . , 1992 J. Virol , 66, 1432-41; Weerasinghe et al . , 1991 J. Virol , 65, 5531-4; Ojwang et al . , 1992 Proc . Natl . Acad . Sci . USA 89, 10802-6; Chen et al . , 1992 Nucleic Acids Res . , 20, 4581-9; Sarver et al . , 1990 Science 247, 1222-1225; Thompson et al . , 1995 Nucleic Acids Res . 23, 2259) . Those skilled in the art realize that any nucleic acid can be expressed in eukaryotic cells from the appropriate DNA/RNA vector. The activity of such nucleic acids can be augmented by their release from the primary transcript by a ribozyme (Draper et al . , PCT W093/23569, and Sullivan et al . , PCT WO94/02595, both hereby incorporated in their totality by reference herein; Ohkawa et al . , 1992 Nucleic Acids Symp. Ser. , 27, 15-6; Taira et al . , 1991, Nucleic Acids Res., 19, 5125-30; Ventura et al . , 1993 Nucleic Acids Res., 21. 3249-55; Chowrira et al . , 1994 J. Biol. Chem. 269, 25856) . Such nucleic acids are useful for the prevention of the diseases and conditions discussed above, and any other diseases or conditions that are related to the levels of VEGF-R (specifically flt-1 and flk-1/KDR) in a cell or tissue. By "related" is meant that the reduction of VEGF-R (specifically flt-1 and flk-1/KDR) RNA levels and thus reduction in the level of the respective protein will relieve, to some extent, the symptoms of the disease or condition. Ribozymes are added directly, or can be complexed with cationic lipids, packaged within liposomes, or other¬ wise delivered to target cells or tissues. The nucleic acid or nucleic acid complexes can be locally administered to relevant tissues ex vivo, or in vivo through injection, infusion pump or stent, with or without their incorpora¬ tion in biopolymers. In preferred embodiments, the ribozymes have binding arms which are complementary to the sequences in Tables II to IX. Examples of such ribozymes also are shown in Tables II to IX. Examples of such ribo ¬ zymes consist essentially of sequences defined in these Tables. By "consists essentially of" is meant that the active ribozyme contains an enzymatic center equivalent to those in the examples, and binding arms able to bind mRNA such that cleavage at the target site occurs. Other sequences may be present which do not interfere with such cleavage. In another aspect of the invention, ribozymes that cleave target RNA molecules and inhibit VEGF-R (specific¬ ally flt-1 and flk-1/KDR) activity are expressed from transcription units inserted into DNA or RNA vectors. The recombinant vectors are preferably DNA plasmids or viral vectors . Ribozyme expressing viral vectors could be con¬ structed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. Preferably, the recombinant vectors capable of expressing the ribo¬ zymes are delivered as described above, and persist in target cells. Alternatively, viral vectors may be used that provide for transient expression of ribozymes . Such vectors might be repeatedly administered as necessary. Once expressed, the ribozymes cleave the target mRNA. Delivery of ribozyme expressing vectors could be systemic, such as by intravenous or intramuscular administration, by administration to target cells ex-planted from the patient followed by reintroduction into the patient, or by any other means that would allow for introduction into the desired target cell. By "vectors" is meant any nucleic acid- and/or viral- based technique used to deliver a desired nucleic acid. Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims. Description Of The Preferred Embodiments First the drawings will be described briefly. Drawings Figure 1 is a diagrammatic representation of the hammerhead ribozyme domain known in the art. Stem II can be ≥ 2 base-pair long. Figure 2a is a diagrammatic representation of the hammerhead ribozyme domain known in the art; Figure 2b is a diagrammatic representation of the hammerhead ribozyme as divided by Uhlenbeck (1987, Nature, 327, 596-600) into a substrate and enzyme portion; Figure 2c is a similar diagram showing the hammerhead divided by Haseloff and Gerlach (1988, Nature, 334, 585-591) into two portions; and Figure 2d is a similar diagram showing the hammerhead divided by Jeffries and Syτnons (1989, Nucl . Acids . Res . , 17, 1371-1371) into two portions. Figure 3 is a diagramatic representation of the general structure of a hairpin ribozyme. Helix 2 (H2) is provided with a least 4 base pairs (i.e., n is 1, 2, 3 or 4) and helix 5 can be optionally provided of length 2 or more bases (preferably 3 - 20 bases, i . e . , m is from 1 - 20 or more) . Helix 2 and helix 5 may be covalently linked by one or more bases ( i . e . , r is ≥ 1 base) . Helix 1, 4 or 5 may also be extended by 2 or more base pairs ( e . g. , 4 - 20 base pairs) to stabilize the ribozyme structure, and preferably is a protein binding site. In each instance, each N and N' independently is any normal or modified base and each dash represents a potential base-pairing inter- action. These nucleotides may be modified at the sugar, base or phosphate. Complete base-pairing is not required in the helices, but is preferred. Helix 1 and 4 can be of any size ( i . e . , o and p is each independently from 0 to any number, e . g. , 20) as long as some base-pairing is maintained. Essential bases are shown as specific bases in the structure, but those in the art will recognize that one or more may be modified chemically (abasic, base, sugar and/or phosphate modifications) or replaced with another base without significant effect. Helix 4 can be formed from two separate molecules, i.e., without a connecting loop. The connecting loop when present may be a ribonucleotide with or without modifications to its base, sugar or phosphate, "q" is ≥ 2 bases. The connect¬ ing loop can also be replaced with a non-nucleotide linker molecule. H refers to bases A, U, or C. Y refers to pyrimidine bases. " " refers to a covalent bond. Figure 4 is a representation of the general structure of the hepatitis delta virus ribozyme domain known in the art. Figure 5 is a representation of the general structure of the VS RNA ribozyme domain. Figure 6 is a schematic representation of an RNAseH accessibility assay. Specifically, the left side of Figure 6 is a diagram of complementary DNA oligonucleo¬ tides bound to accessible sites on the target RNA. Complementary DNA oligonucleotides are represented by broad lines labeled A, B, and C. Target RNA is repre¬ sented by the thin, twisted line. The right side of Figure 6 is a schematic of a gel separation of uncut target RNA from a cleaved target RNA. Detection of target RNA is by autoradiography of body-labeled, T7 transcript. The bands common to each lane represent uncleaved target RNA; the bands unique to each lane represent the cleaved products. Figure 7 shows the effect of hammerhead ribozymes targeted against flt-1 receptor on the binding of VEGF to the surface of human microvascular endothelial cells. Sequences of the ribozymes used are shown in Table II; the length of stem II region is 3 bp. The hammerhead ribo¬ zymes were chemically modified such that the ribozyme consists of ribose residues at five positions (see Figure 11) ; U4 and U7 positions contain 2' -NH 2 modifications, the remaining nucleotide positions contain 2'-0-methyl substi¬ tutions; four nucleotides at the 5' terminus contains phosphorothioate substitutions. Additionally, the 3' end of the ribozyme contains a 3' -3' linked inverted abasic deoxyribose. The results of two separate experiments are shown as separate bars for each set . Each bar represents the average of triplicate samples. The standard deviation is shown with error bars. For the flt-1 data, 500 nM ribozyme (3:1 charge ratio with LipofectAMINE ® ) was used. Control 1-10 is the control for ribozymes 307-2797, control 11-20 is the control for ribozymes 3008-5585. The Control 1-10 and Control 11-20 represent the treatment of cells with LipofectAMINE ® alone without any ribozymes. Figure 8 shows the effect of hammerhead ribozymes targeted against KDR receptor on the binding of VEGF to KDR on the surface of human microvascular endothelial cells. Sequences of the ribozymes used are shown in Table IV; the length of stem II region is 3 bp. The hammerhead ribozymes were chemically modified such that the ribozyme consists of ribose residues at five positions (see Figure 11) ; U4 and U7 positions contain 2 ' -NH 2 modifications, the remaining nucleotide positions contain 2'-0-methyl substi¬ tutions; four nucleotides at the 5' terminus contains phosphorothioate substitutions. Additionally, the 3' end of the ribozyme contains a 3'-3' linked inverted abasic deoxyribose. The Control 1-10 and Control 11-20 represent the treatment of cells with LipofectAMINE ® alone without any ribozymes. Irrel. RZ, is a control experiment wherein the cells are treated with a non-KDR-targeted ribozyme complexed with Lipofectamine ® . 200 nM ribozyme (3:1 charge ratio with LipofectAMINE ® ) was used. In addition to the KDR-targeted ribozymes, the effect on VEGF binding of a ribozyme targeted to an irrelevant mRNA (irrel. RZ) is also shown. Because the affinity of KDR for VEGF is about 10-fold lower than the affinity of flt-1 for VEGF, a higher concentration of VEGF was used in the binding assay. Figure 9 shows the specificity of hammerhead ribo¬ zymes targeted against flt-1 receptor. Inhibition of the binding of VEGF, urokinase plasminogen activator (UPA) and fibroblast growth factor (FGF) to their corresponding receptors as a function of anti-FLT ribozymes is shown. The sequence and description of the ribozymes used are as described under Figure 7 above. The average of triplicate samples is given; percent inhibition as calculated below. Figure 10 shows the inhibition of the proliferation of Human aortic endothelial cells (HAEC) mediated by phosphorothioate antisense oligodeoxynucleotides targeted against human KDR receptor RNA. Cell proliferation (O.D. 490) as a function of antisense oligodeoxynucleotide concentration is shown. KDR 21AS represents a 21 nt phosphorothioate antisense oligodeoxynucleotide targeted against KDR RNA. KDR 21 Scram represents a 21 nt phosphorothioate oligodeoxynucleotide having a scrambled sequence. LF represents the lipid carrier Lipofectin. Figure 11 shows in vi tro cleavage of flt-1 RNA by hammerhead ribozymes. A) diagrammatic representation of hammerhead ribozymes targeted against flt-1 RNA. The hammerhead (HH) ribozymes were chemically modified such that the ribozyme consists of ribose residues at five positions; U4 and U7 positions contain 2' -NH 2 modifica¬ tions, the remaining nucleotide positions contain 2'-0-methyl substitutions; four nucleotides at the 5' terminus contains phosphorothioate substitutions. Additionally, the 3' end of the ribozyme contains a 3' -3' linked inverted abasic deoxyribose (designated as 3'-iH) . 1358 HH-A and 4229 HH-A contain 3 base-paired stem II region. 1358 HH-B and 4229 HH-B contain 4 base-paired stem II region. B) and C) shows in vi tro cleavage kinetics of HH ribozymes targeted against sites 1358 and 4229 within the flt-1 RNA. Figure 12 shows inhibition of human microvascular endothelial cell proliferation mediated by anti-flt-1 hammerhead ribozymes. A) Diagrammatic representation of hammerhead (HH) ribozymes targeted against sites 1358 and 4229 within the the flt-1 RNA. B) Graphical representa¬ tion of the inhibition of cell proliferation mediated by 1358HH and 4229HH ribozymes. Figure 13 shows inhibition of human microvascular endothelial cell proliferation mediated by anti-KDR hammerhead ribozymes. The figure is a graphical represen¬ tation of the inhibition of cell proliferation mediated by hammerhead ribozymes targeted against sites 527, 730, 3702 and 3950 within the KDR RNA. Irrelevant HH RZ is a hammerhead ribozyme targeted to an irrelevant target. All of these ribozymes, including the Irrelevant HH RZ, were chemically modified such that the ribozyme consists of ribose residues at five positions; U4 and U7 positions contain 2' -NH 2 modifications, the remaining nucleotide positions contain 2'-0-methyl substitutions; four nucleotides at the 5' termini contain phosphorothioate substitutions. Additionally, the 3' end of the ribozyme contains a 3'-3' linked inverted abasic deoxyribose (3'-iH) . Figure 14 shows in vi tro cleavage of KDR RNA by hammerhead ribozymes. The hammerhead (HH) ribozymes were chemically modified such that the ribozyme consists of ribose residues at five positions; U4 and U7 positions contain 2' -NH 2 modifications, the remaining nucleotide positions contain 2'-0-methyl substitutions. Addition¬ ally, the 3' end of the ribozyme contains a 3' -3' linked inverted abasic deoxyribose (designated as 3'-iH) . 726 HH and 527 HH contain 4 base-paired stem II region. Percent in vi tro cleavage kinetics as a function of time of HH ribozymes targeted against sites 527 and 726 within the KDR RNA is shown. Figure 15 shows in vi tro cleavage of KDR RNA by hammerhead ribozymes. The hammerhead (HH) ribozymes were chemically modified such that the ribozyme consists of ribose residues at five positions; U4 and U7 positions contain 2 ' -NH 2 modifications, the remaining nucleotide positions contain 2'-0-methyl substitutions. Addition¬ ally, the 3' end of the ribozyme contains a 3 '-3' linked inverted abasic deoxyribose (designated as 3'-iH) . 3702 HH and 3950 HH contain 4 base-paired stem II region. Percentin vitro cleavage kinetics as a function of time of HH ribozymes targeted against sites 3702 and 3950 within the KDR RNA is shown. Figure 16 shows in vi tro cleavage of RNA by hammer- head ribozymes that are targeted to sites that are conserved between flt-1 and KDR RNA. The hammerhead (HH) ribozymes were chemically modified such that the ribozyme consists of ribose residues at five positions; U4 and U7 positions contain 2' -NH 2 modifications, the remaining nucleotide positions contain 2'-0-methyl substitutions. Additionally, the 3' end of the ribozyme contains a 3'-3' linked inverted abasic deoxyribose (designated as 3'-iH) . FLT/KDR-I HH ribozyme was synthesized with either a 4 base-paired or a 3 base-paired stem II region. FLT/KDR-I HH can cleave site 3388 within flt-1 RNA and site 3151 within KDR RNA. Percent in vi tro cleavage kinetics as a function of time of HH ribozymes targeted against sites 3702 and 3950 within the KDR RNA is shown. Figure 17 shows inhibition of human microvascular endothelial cell proliferation mediated by anti-KDR and anti-fit-1 hammerhead ribozymes. The figure is a graph- ical representation of the inhibition of cell prolifera¬ tion mediated by hammerhead ribozymes targeted against sites KDR sites-527, 726 or 3950 or flt-1 site 4229. The figure also shows enhanced inhibition of cell prolifera¬ tion by a combination of flt-1 and KDR hammerhead ribo- zymes. 4229+527, indicates the treatment of cells with both the fit 4229 and the KDR 527 ribozymes. 4229+726, indicates the treatment of cells with both the fit 4229 and the KDR 726 ribozymes. 4229+3950, indicates the treatment of cells with both the fit 4229 and the KDR 3950 ribozymes. VEGF -, indicates the basal level of cell proliferation in the absence of VEGF. A, indicates catalytically active ribozyme; I, indicates catalytically inactive ribozyme. All of these ribozymes were chemically modified such that the ribozyme consists of ribose residues at five positions; U4 and U7 positions contain 2' -NH 2 modifications, the remaining nucleotide positions contain 2'-0-methyl substitutions; four nucleotides at the 5' termini contain phosphorothioate substitutions. Additionally, the 3' end of the ribozyme contains a 3' -3' linked inverted abasic deoxyribose (3'-iH) . Figure 18 shows the inhibition of VEGF-induced angio¬ genesis in rat cornea mediated by anti-flt-1 hammerhead ribozyme. All of these ribozymes were chemically modified such that the ribozyme consists of ribose residues at five positions; U4 position contains 2'-C-allyl modifications, the remaining nucleotide positions contain 2'-0-methyl substitutions; four nucleotides at the 5' termini contain phosphorothioate substitutions. Additionally, the 3' end of the ribozyme contains a 3'-3' linked inverted abasic deoxyribose (3'-iH) . A decrease in the Surface Area corresponds to a reduction in angiogenesis. VEGF alone, corresponds to treatment of the cornea with VEGF and no ribozymes. Vehicle alone, corresponds to the treatment of the cornea with the carrier alone and no VEGF. This control gives a basal level of Surface Area. Active 4229 HH, corresponds to the treatment of cornea with the flt-1 4229 HH ribozyme in the absence of any VEGF. This control also gives a basal level of Surface Area. Active 4229 HH + VEGF, corresponds to the co-treatment of cornea with the flt-1 4229 HH ribozyme and VEGF. Inactive 4229 HH + VEGF, corresponds to the co-treatment of cornea with a cata- lytically inactive version of 4229 HH ribozyme and VEGF. Ribozymes Ribozymes of this invention block to some extent VEGF-R (specifically flt-1 and flk-1/KDR) production and can be used to treat disease or diagnose such disease. Ribozymes will be delivered to cells in culture, to cells or tissues in animal models of angiogenesis and/or RA and to human cells or tissues ex vivo or in vivo . Ribozyme cleavage of VEGF-R RNAs (specifically RNAs that encode flt-1 and flk-1/KDR) in these systems may alleviate disease symptoms. Target sites Targets for useful ribozymes can be determined as disclosed in Draper et al . , International PCT Publication No. WO 95/13380, and hereby incorporated by reference herein in totality. Other examples include the following PCT applications which concern inactivation of expression of disease-related genes: WO 95/23225, WO 95/13380, WO 94/02595, incorporated by reference herein. Rather than repeat the guidance provided in those documents here, below are provided specific examples of such methods, not limiting to those in the art. Ribozymes to such targets are designed as described in those applications and syn¬ thesized to be tested in vi tro and in vivo, as also described. The sequence of human and mouse flt-1, KDR and/or flk-1 mRNAs were screened for optimal ribozyme target sites using a computer folding algorithm. Hammerhead or hairpin ribozyme cleavage sites were identified. These sites are shown in Tables II to IX (all sequences are 5' to 3' in the tables; X can be any base-paired sequence, the actual sequence is not relevant here) . The nucleotide base position is noted in the Tables as that site to be cleaved by the designated type of ribozyme. While mouse and human sequences can be screened and ribozymes there- after designed, the human targeted sequences are of most utility. However, as discussed in Stinchcomb et al . , "Method and Composition for Treatment of Restenosis and Cancer Using Ribozymes," filed May 18, 1994, U.S.S.N. 08/245,466, mouse targeted ribozymes may be useful to test efficacy of action of the ribozyme prior to testing in humans. The nucleotide base position is noted in the Tables as that site to be cleaved by the designated type of ribozyme. Hammerhead or hairpin ribozymes were designed that could bind and cleave target RNA in a sequence-specific manner. The ribozymes were individually analyzed by computer folding (Jaeger et al . , 1989 Proc . Natl . Acad. Sci . USA, 86, 7706) to assess whether the ribozyme sequences fold into the appropriate secondary structure. Those ribozymes with unfavorable intramolecular inter¬ actions between the binding arms and the catalytic core were eliminated from consideration. Varying binding arm lengths can be chosen to optimize activity. Referring to Figure 6, mRNA is screened for access- ible cleavage sites by the method described generally in Draper et al . , PCT W093/23569, hereby incorporated by reference herein. Briefly, DNA oligonucleotides complementary to potential hammerhead or hairpin ribozyme cleavage sites were synthesized. A polymerase chain reaction is used to generate substrates for T7 RNA polymerase transcription from human and mouse flt-1, KDR and/or flk-1 cDNA clones. Labeled RNA transcripts are synthesized in vi tro from the templates. The oligonucleo¬ tides and the labeled transcripts were annealed, RNAseH was added and the mixtures were incubated for the desig¬ nated times at 37 * C. Reactions are stopped and RNA separated on sequencing polyacrylamide gels. The percent¬ age of the substrate cleaved is determined by autoradio- graphic quantitation using a Phosphorlmaging system. From these data, hammerhead or hairpin ribozyme sites are chosen as the most accessible. Ribozymes of the hammerhead or hairpin motif were designed to anneal to various sites in the mRNA message. The binding arms are complementary to the target site sequences described above. The ribozymes were chemically synthesized. The method of synthesis used follows the procedure for normal RNA synthesis as described in Usman et al . , 1987 J. Am . Chem . Soc , 109, 7845; Scaringe et al . , 1990 Nuclei c Acids Res . , 18, 5433; and Wincott et al., 1995 Nuclei c Acids Res . 23, 2677-2684 and makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5' -end, and phosphora- midites at the 3 '-end. Small scale synthesis were conducted on a 394 Applied Biosystems, Inc. synthesizer using a modified 2.5 μmol scale protocol with a 5 min coupling step for alkylsilyl protected nucleotides and 2.5 min coupling step for 2 ' -O-methylated nucleotides. Table XI outlines the amounts, and the contact times, of the reagents used in the synthesis cycle. A 6.5-fold excess (163 μL of 0.1 M = 16.3 μmol) of phosphoramidite and a 24-fold excess of S-ethyl tetrazole (238 μL of 0.25 M = 59.5 μmol) relative to polymer-bound 5' -hydroxyl was used in each coupling cycle. Average coupling yields on the 394 Applied Biosystems, Inc. synthesizer, determined by colorimetric quantitation of the trityl fractions, were 97.5-99%. Other oligonucleotide synthesis reagents for the 394 Applied Biosystems, Inc. synthesizer: detritylation solution was 2% TCA in methylene chloride (ABI) ; capping was performed with 16% N-methyl imidazole in THF (ABI) and 10% acetic anhydride/10% 2,6-lutidine in THF (ABI); oxidation solution was 16.9 mM I 2 , 49 mM pyridine, 9% water in THF (Millipore) . B & J Synthesis Grade acetonitrile was used directly from the reagent bottle. 5-Ethyl tetra- zole solution (0.25 M in acetonitrile) was made up from the solid obtained from American International Chemical, Inc . Deprotection of the RΝA was performed as follows. The polymer-bound oligoribonucleotide, trityl-off, was trans- ferred from the synthesis column to a 4mL glass screw top vial and suspended in a solution of methylamine (MA) at 65 * C for 10 min. After cooling to -20 * C, the supernatant was removed from the polymer support . The support was washed three times with 1.0 mL of EtOH:MeCΝ:H 2 0/3 : 1 : 1, vortexed and the supernatant was then added to the first supernatant. The combined supernatants, containing the oligoribonucleotide, were dried to a white powder. The base-deprotected oligoribonucleotide was resus¬ pended in anhydrous TEA»HF/NMP solution (250 μL of a solution of 1.5mL N-methylpyrrolidinone , 750 μL TEA and 1.0 mL TEA*3HF to provide a 1.4M HF concentration) and heated to 65 * C for 1.5 h. The resulting, fully depro¬ tected, oligomer was quenched with 50 mM TEAB (9 mL) prior to anion exchange desalting. For anion exchange desalting of the deprotected oligomer, the TEAB solution was loaded onto a Qiagen 500 ® anion exchange cartridge (Qiagen Inc.) that was prewashed with 50 mM TEAB (10 mL) . After washing the loaded cartridge with 50 mM TEAB (10 mL) , the RΝA was eluted with 2 M TEAB (10 mL) and dried down to a white powder. Inactive hammerhead ribozymes were synthesized by substituting a U for G 5 and a U for A 14 (numbering from Hertel, K. J. , et al . , 1992, Nucleic Acids Res . . 20, 3252) . The average stepwise coupling yields were > 98% (Wincott et al . , 1995 Nucleic Acids Res . 23, 2677-2684) . Hairpin ribozymes are synthesized in two parts and annealed to reconstruct the active ribozyme (Chowrira and Burke, 1992 Nucleic Acids Res . , 20, 2835-2840) . Ribozymes are also synthesized from DNA templates using bacterio- phage T7 RNA polymerase (Milligan and Uhlenbeck, 1989, Methods Enzymol . 180, 51) . All ribozymes are modified extensively to enhance stability by modification with nuclease resistant groups, for example, 2'-amino, 2'-C-allyl, 2'-flouro, 2'-0-methyl, 2'-H (for a review see Usman and Cedergren, 1992 TIBS 17, 34; Usman et al . , 1994 Nucleic Acids Symp . Ser. 31, 163) . Ribozymes are purified by gel electrophoresis using general methods or are purified by high pressure liquid chromatography (HPLC; See Usman et al . , PCT Publication No. W095/23225, the totality of which is hereby incor- porated herein by reference) and are resuspended in water. The sequences of the ribozymes that are chemically synthesized, useful in this study, are shown in Tables II to IX. Those in the art will recognize that these sequences are representative only of many more such sequences where the enzymatic portion of the ribozyme (all but the binding arms) is altered to affect activity. Stem-loop IV sequence of hairpin ribozymes listed in for example Table III (5' -CACGUUGUG-3 ' ) can be altered (substitution, deletion, and/or insertion) to contain any sequence, provided a minimum of two base-paired stem structure can form. The sequences listed in Tables II to IX may be formed of ribonucleotides or other nucleotides or non-nucleotides. Such ribozymes are equivalent to the ribozymes described specifically in the Tables. Optimizing Ribozyme Activity Ribozyme activity can be optimized as described by Stinchcomb et al . , supra. The details will not be repeated here, but include altering the length of the ribozyme binding arms (stems I and III, see Figure 2c) , or chemically synthesizing ribozymes with modifications that prevent their degradation by serum ribonucleases (see e . g. , Eckstein et al . , International Publication No. WO 92/07065; Perrault et al . , 1990 Nature 344, 565; Pieken et al . , 1991 Science 253, 314; Usman and Cedergren, 1992 Trends in Biochem . Sci . 17, 334; Usman et al . , Interna¬ tional Publication No. WO 93/15187; Rossi et al . , International Publication No. WO 91/03162; Beigelman et al . , 1995 J. Biol Chem . in press; as well as Sproat, US Patent No. 5,334,711 which describe various chemical modifications that can be made to the sugar moieties of enzymatic RNA molecules) . Modifications which enhance their efficacy in cells, and removal of stem II bases to shorten RNA synthesis times and reduce chemical require- ments are desired. (All these publications are hereby incorporated by reference herein) . Sullivan, et al . , supra , describes the general methods for delivery of enzymatic RNA molecules. Ribozymes may be administered to cells by a variety of methods known to those familiar to the art, including, but not restricted to, encapsulation in liposomes, by ionto¬ phoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres. For some indications, ribozymes may be directly delivered ex vivo to cells or tissues with or without the aforementioned vehicles. Alternatively, the RNA/vehicle combination is locally delivered by direct injection or by use of a catheter, infusion pump or stent . Other routes of delivery include, but are not limited to, intravascular, intramuscular, subcutaneous or joint injection, aerosol inhalation, oral (tablet or pill form) , topical, systemic, ocular, intraperitoneal and/or intra- thecal delivery. More detailed descriptions of ribozyme delivery and administration are provided in Sullivan et al . , supra and Draper et al . , supra which have been incorporated by reference herein. Another means of accumulating high concentrations of a ribozyme (s) within cells is to incorporate the ribozyme- encoding sequences into a DNA or RNA expression vector. Transcription of the ribozyme sequences are driven from a promoter for eukaryotic RNA polymerase I (pol I) , RNA polymerase II (pol II) , or RNA polymerase III (pol III) . Transcripts from pol II or pol III promoters will be expressed at high levels in all cells; the levels of a given pol II promoter in a given cell type will depend on the nature of the gene regulatory sequences (enhancers, silencers, etc.) present nearby. Prokaryotic RNA polymer¬ ase promoters are also used, providing that the prokary¬ otic RNA polymerase enzyme is expressed in the appropriate cells (Elroy-Stein and Moss, 1990 Proc. Natl. Acad. Sci. U S A, 87, 6743-7; Gao and Huang 1993 Nucleic Acids Res., 21, 2867-72; Lieber et al . , 1993 Methods Enzymol . , 217, 47-66; Zhou et al . , 1990 Mol. Cell. Biol., 10, 4529-37; Thompson et al . , 1995 supra) . Several investigators have demonstrated that ribozymes expressed from such promoters can function in mammalian cells (e.g. Kashani-Sabet et al . , 1992 Antisense Res. Dev. , 2, 3-15; Ojwang et al . , 1992 Proc. Natl. Acad. Sci. U S A, 89, 10802-6; Chen et al., 1992 Nucleic Acids Res., 20, 4581-9; Yu et al . , 1993 Proc. Natl. Acad. Sci. U S A, 90, 6340-4; L'Huillier et al., 1992 E BO J. 11, 4411-8; Lisziewicz et al. , 1993 Proc. Natl. Acad. Sci. U. S. A., 90, 8000-4; Thompson et al . , 1995 Nucleic Acids Res. 23, 2259) . The above ribo¬ zyme transcription units can be incorporated into a variety of vectors for introduction into mammalian cells, including but not restricted to, plasmid DNA vectors, viral DNA vectors (such as adenovirus or adeno-associated virus vectors) , or viral RNA vectors (such as retroviral or alphavirus vectors) . In a preferred embodiment of the invention, a transcription unit expressing a ribozyme that cleaves RNAs that encode flt-1, KDR and/or flk-1 are inserted into a plasmid DNA vector or an adenovirus or adeno-associated virus DNA viral vector or a retroviral RNA vector. Viral vectors have been used to transfer genes and lead to either transient or long term gene expression (Zabner et al . , 1993 Cell 75, 207; Carter, 1992 Curr. Qpi . Biotech. 3, 533) . The adenovirus, AAV or retroviral vector is delivered as recombinant viral particles. The DNA may be delivered alone or complexed with vehicles (as described for RNA above) . The recombinant adenovirus or AAV or retroviral particles are locally administered to the site of treatment, e.g. , through incubation or inhalation in vivo or by direct application to cells or tissues ex vivo. Retroviral vectors have also been used to express ribozymes in mammalian cells (Ojwang et al . , 1992 supra; Thompson et al . , 1995 supra) . flt-1, KDR and/or flk-1 are attractive nucleic acid-based therapeutic targets by several criteria. The interaction between VEGF and VEGF-R is well-established. Efficacy can be tested in well-defined and predictive animal models. Finally, the disease conditions are serious and current therapies are inadequate. Whereas protein-based therapies would inhibit VEGF activity nucleic acid-based therapy provides a direct and elegant approach to directly modulate flt-1, KDR and/or flk-1 expression. Because flt-1 and KDR mRNAs are highly homologous in certain regions, some ribozyme target sites are also homologous (see Table X) . In this case, a single ribozyme will target both flt-1 and KDR mRNAs. At partially homologous sites, a single ribozyme can sometimes be designed to accomodate a site on both mRNAs by including G/U basepairing. For example, if there is a G present in a ribozyme target site in KDR mRNA at the same position there is an A in the flt-1 ribozyme target site, the ribozyme can be synthesized with a U at the complementary position and it will bind both to sites. The advantage of one ribozyme that targets both VEGF-R mRNAs is clear, especially in cases where both VEGF receptors may con- tribute to the progression of angiogenesis m the disease state. "Angiogenesis" refers to formation of new blood vessels which is an essential process in reproduction, development and wound repair. "Tumor angiogenesis" refers to the induction of the growth of blood vessels from surrounding tissue into a solid tumor. Tumor growth and tumor metastasis are dependent on angiogenesis (for a review see Folkman, 1985 supra ; Folkman 1990 J. Natl . Cancer Inst . , 82, 4; Folkman and Shing, 1992 J. Biol . Chem . 267, 10931) . Angiogenesis plays an important role in other diseases such as arthritis wherein new blood vessels have been shown to invade the joints and degrade cartilage (Folkman and Shing, supra) . "Retinopathy" refers to inflammation of the retina and/or degenerative condition of the retina which may lead to occlusion of the retina and eventual blindness. In "diabetic retinopathy" angiogenesis causes the capillaries in the retina to invade the vitreous resulting in bleeding and blindness which is also seen in neonatal retinopathy (for a review see Folkman, 1985 supra ; Folkman 1990 supra ; Folkman and Shing, 1992 supra) . Example 1: flt-1, KDR and/or flk-1 ribozymes By engineering ribozyme motifs applicant has designed several ribozymes directed against flt-1, KDR and/or flk-1 encoded mRNA sequences. These ribozymes were synthesized with modifications that improve their nuclease resistance (Beigelman et al . , 1995 J Biol . Chem . 270, 25702) and enhance their activity in cells. The ability of ribozymes to cleave target sequences in vi tro was evaluated essen¬ tially as described in Thompson et al . , PCT Publication No. WO 93/23057; Draper et al . , PCT Publication No. WO 95/04818. Example 2 : Effect of ribozymes on the binding of VEGF to flt-1. KDR and/or flk-1 receptors Several common human cell lines are available that express endogenous flt-1, KDR and/or flk-1. flt-1, KDR and/or flk-1 can be detected easily with monoclonal antibodies. Use of appropriate fluorescent reagents and fluorescence-activated cell-sorting (FACS) will permit direct quantitation of surface flt-1, KDR and/or flk-1 on a cell-by-cell basis. Active ribozymes are expected to directly reduce flt-1, KDR and/or flk-1 expression and thereby reduce VEGF binding to the cells. In this example, human umbelical cord microvascular endothelial cells were used. Cell Preparation: Plates are coated with 1.5% gelatin and allowed to stand for one hour. Cells (e.g., microvascular endo¬ thelial cells derived from human umbilical cord vein) are plated at 20,000 cells/well (24 well plate) in 200 ml growth media and incubated overnight (- 1 doubling) to yield -40,000 cells (75-80% confluent) . Ribozyme treatment : Media is removed from cells and the cells are washed two times with 300 ml IX PBS: Ca 2+ : Mg 2 * mixture. A complex of 200-500 nM ribozyme and LipofectAMINE ® (3:1 lipid: phosphate ratio) in 200 ml OptiMEM ® (5% FBS) was added to the cells. The cells are incubated for 6 hr (equivalent to 2-3 VEGF-R turnovers) . 15 I VEGF binding assay: The assay is carried out on ice to inhibit internali- zation of VEGF during the experiment . The media contain¬ ing the ribozyme is removed from the cells and the cells are washed twice with with 300 ml IX PBS: Ca 2 * : Mg 2 * mixture containing 1% BSA. Appropriate 12S I VEGF solution (100,000 cpm/well, +/- 10 X cold IX PBS, 1% BSA) was applied to the cells. The cells are incubated on ice for 1 h. 125 I VEGF-containing solution is removed and the cells are washed three times with with 300 ml IX PBS: Ca 2+ : Mg 2+ mixture containing 1% BSA. To each well 300 ml of 100 mM Tris-HCI, pH 8.0, 0.5% Triton X-100 was added and the the mixture was incubated for 2 min. The 125 I VEGF-binding was quantitated using standard scintillation counting techniques. Percent inhibition was calculated as follows: Percent Inhibition = cpm 125 I VEGF bound by the ribozyme-treated samples x 100 cp 125 I VEGF bound by the Control sample Example 3 : Effect of hammerhead ribozymes targeted against flt-1 receptor on the binding of VEGF Hammerhead ribozymes targeted to twenty sites within flt-1 RNA were synthesized as described above. Sequence of the ribozymes used are shown in Table II; the length of stem II region is 3 bp. The hammerhead ribozymes were chemically modified such that the ribozyme consists of ribose residues at five positions; U4 and U7 positions contain 2 ' -NH 2 modifications, the remaining nucleotide positions contain 2'-0-methyl substitutions; four nucleo- tides at the 5' terminus contains phosphorothioate substitutions. Additionally, 3' end of the ribozyme contains a 3'-3' linked inverted abasic ribose. Referring to Figure 7, the effect of hammerhead ribozymes targeted against flt-1 receptor on the binding of VEGF to flt-1 on the surface of human microvascular endothelial cells is shown. The majority of the ribozymes tested were able to inhibit the expression of flt-1 and thereby were able to inhibit the binding of VEGF. In order to determine the specificity of ribozymes targeted against flt-1 RNA, the effect of five anti-flt-1 ribozymes on the binding of VEGF, UPA (urokinase plasmino- gen activator) and FGF (fibroblast growth factor) to their corresponding receptors were assayed. As shown in Figure 9, there was significant inhibition of VEGF binding to its receptors on cells treated with anti-flt-1 ribozymes. There was no specific inhibition of the binding of UPA and FGF to their corresponding receptors. These data strongly suggest that anti-fit-1 ribozymes specifically cleave flt-1 RNA and not RNAs encoding the receptors for UPA and FGF, resulting in the inhibition of flt-1 receptor expres- sion on the surface of the cells. Thus the ribozymes are responsible for the inhibition of VEGF binding but not the binding of UPA and FGF. Example 4 : Effect of hammerhead ribozymes targeted against KDR receptor on the binding of VEGF Hammerhead ribozymes targeted to twenty one sites within KDR RNA were synthesized as described above. Sequence of the ribozymes used are shown in Table IV; the length of stem II region is 3 bp. The hammerhead ribo¬ zymes were chemically modified such that the ribozyme consists of ribose residues at five positions; U4 and U7 positions contain 2'-NH 2 modifications, the remaining nucleotide positions contain 2 ' -O-methyl substitutions; four nucleotides at the 5' terminus contains phosphoro¬ thioate substitutions. Additionally, the 3' end of the ribozyme contains a 3 '-3' linked inverted abasic deoxyribose. Referring to Figure 8, the effect of hammerhead ribozymes targeted against KDR receptor on the binding of VEGF to KDR on the surface of human microvascular endo- thelial cells is shown. A majority of the ribozymes tested were able to inhibit the expression of KDR and thereby were able to inhibit the binding of VEGF. As a control, the cells were treated with a ribozyme that is not targeted towards KDR RNA (irrel. RZ) ; there was no specific inhibition of VEGF binding. The results from this control experiment strongly suggest that the inhibi- tion of VEGF binding observed with anti-KDR ribozymes is a ribozyme-mediated inhibition. Example 5 : Effect of ribozymes targeted against VEGF receptors on cell proliferation Cell Preparation: 24-well plates are coated with 1.5% gelatin (porcine skin 300 bloom) . After 1 hr, excess gelatin is washed off of the plate. Microvascular endothelial cells are plated at 5,000 cells/well (24 well plate) in 200 ml growth media. The cells are allowed to grow for - 18 hr (- 1 doubling) to yield -10,000 cells (25-30% confluent) . Ribozyme treatment : Media is removed from the cells, and the cells are washed two times with 300 ml IX PBS: Ca 2 * : Mg 2 * mixture. For anti-flt-1 HH ribozyme experiment (Figure 12) a complex of 500 nM ribozyme; 15 mM LFA (3:1 lipid:phosphate ratio) in 200 ml OptiMEM (5% FCS) media was added to the cells. Incubation of cells is carried out for 6 hr (equivalent to 2-3 VEGF receptor turnovers) . For anti-KDR HH ribozyme experiment (Figure 13) a complex of 200 nM ribozyme; 5.25 mM LFA (3:1 lipid: phosphate ratio) in 200 ml OptiMEM (5% FCS) media was added to the cells. Incubation of cells is carried out for 3 hr. Proliferation: After three or six hours, the media is removed from the cells and the cells are washed with 300 ml IX PBS: Ca 2* : Mg 2 * mixture. Maintenance media (contains dialyzed 10% FBS) +/- VEGF or basic FGF at 10 ng/ml is added to the cells. The cells are incubated for 48 or 72 h. The cells are trypsinized and counted (Coulter counter) . Trypan blue is added on one well of each treatment as control. As shown in Figure 12B, VEGF and basic FGF can stimu¬ late human microvascular endothelial cell proliferation. However, treatment of cells with 1358 HH or 4229 HH ribo¬ zymes, targeted against flt-1 mRNA, results in a signifi- cant decrease in the ability of VEGF to stimulate endo¬ thelial cell proliferation. These ribozymes do not inhibit the FGF-mediated stimulation of endothelial cell proliferation. Human microvascular endothalial cells were also treated with hammerhead ribozymes targeted against sites 527, 730, 3702 or 3950 within the KDR mRΝA. As shown in Figure 13, all four ribozymes caused significant inhi¬ bition of VEGF-mediated induction of cell proliferation. No significant inhibition of cell proliferation was observed when the cells were treated with a hammerhead ribozyme targeted to an irrelevant RNA. Additionally, none of the ribozymes inhibited FGF-mediated stimulation of cell proliferation. These results strongly suggest that hammerhead ribozymes targeted against either flt-1 or KDR mRNA can specifically inhibit VEGF-mediated induction of endo¬ thelial cell proliferation. Example 6: Effect of antisense oligonucleotides targeted against VEGF receptors on cell proliferation (colorimetric assay) Following are some of the reagents used in the proliferation assay: Cells : Human aortic endothelial cells (HAEC) from Clonetics ® . Cells at early passage are preferably used. Uptake Medium: EBM (from Clonetics ® ) ; 1% L-Glutamine,-20 mM Hepes,- No serum; No antibiotics. Growth Medium: EGM (from Clonetics ® ) ;FBS to 20%;1% L-Glutamine;20 mM Hepes. Cell Plating: 96-well tissue culture plates are coated with 0.2% gelatin (50 ml/well) . The gelatin is incubated in the wells at room temperature for 15-30 minutes. The gelatin is removed by aspiration and the wells are washed with PBS:Ca 2* : Mg 2* mixture. PBS mixture is left in the wells until cells are ready to be added. HAEC cells were detached by trypsin treatment and resus- pended at 1.25 x 10*/ml in growth medium. PBS is removed from plates and 200 ml of cells (i.e. 2.5 x 10 3 cells/well) are added to each well. The cells are allowed to grow for 48 hours before the proliferation assay. Assay: Growth medium is removed from the wells. The cells are washed twice with PBS:Ca 2* : Mg 2 * mixture without antibiotics. A formulation of lipid/antisense oligo¬ nucleotide (antisense oligonucleotide is used here as a non-limiting example) complex is added to each well (100 ml/well) in uptake medium. The cells are incubated for 2-3 hours at 37'C in C0 2 incubator. After uptake, 100 ml/well of growth medium is added (gives final FBS con¬ centration of 10%) . After approximately 72 hours, 40 ml MTS ® stock solution (made as described by manufacturer) was added to each well and incubated at 37 * C for 1-3 hours, depending on the color development. (For this assay, 2 hours was sufficient) . The intensity of color formation was determined on a plate reader at 490 nM. Phosphorothioate-substituted antisense oligodeoxy- nucleotides were custom synthesized by The Midland Certified Reagent Company ® , Midland, Texas. Following non-limiting antisense oligodeoxynucleotides targeted against KDR RNA were used in the proliferation assay: KDR 21 AS: 5'-GCA GCA CCT TGC TCT CCA TCC-3' SCRAMBLED CONTROL: 5'-CTG CCA ACT TCC CAT GCC TGC-3' As shown in Figure 10, proliferation of HAEC cells are specifically inhibited by increasing concentrations of the phosphorothioate anti-KDR-antisense oligodeoxynucleo¬ tide. The scrambled antisense oligonucleotide is not expected to bind the KDR RNA and therefore is not expected to inhibit KDR expression. As expected, there is no detectable inhibition of proliferation of HAEC cells treated with a phosphorothioate antisense oligonucleotide with scrambled sequence. Example 7: In vi tro cleavage of flt-1 RNA by hammerhead ribozymes Referring to Figure 11A, hammerhead ribozymes (HH) targeted against sites 1358 and 4229 within the flt-1 RNA were synthesized as described above. RNA cleavage assay in vi tro : Substrate RNA was 5' end-labeled using [g- 32 P] ATP and T4 polynucleotide kinase (US Biochemicals) . Cleavage reactions were carried out under ribozyme "excess" condi¬ tions. Trace amount (≤ 1 nM) of 5' end-labeled substrate and 40 nM unlabeled ribozyme were denatured and renatured separately by heating to 90 * C for 2 min and snap-cooling on ice for 10-15 min. The ribozyme and substrate were incubated, separately, at 37"C for 10 min in a buffer containing 50 mM Tris-HCI and 10 mM MgCl 2 . The reaction was initiated by mixing the ribozyme and substrate solu¬ tions and incubating at 37 * c. Aliquots of 5 ml are taken at regular intervals of time and the reaction is quenched by mixing with equal volume of 2X formamide stop mix. The samples are resolved on 20 % denaturing polyacrylamide gels. The results were quantified and percentage of target RNA cleaved is plotted as a function of time. Referring to Figure IIB and 11C, hammerhead ribozymes targeted against sites 1358 and 4229 within the flt-1 RNA are capable of cleaving target RNA efficiently in vi tro . Example 8: In vi tro cleavage of KDR RNA by hammerhead ribozymes In this non-limiting example, hammerhead ribozymes targeted against sites 726, 527, 3702 and 3950 within KDR RNA were synthesized as described above. RNA cleavage reactions were carried out in vi tro essentially as described under Example 7. Referring to Figures 14 and 15, all four ribozymes were able to cleave their cognate target RNA efficiently in a sequence-specific manner. Example 9: In vi tro cleavage of RNA by hammerhead ribo- zvmes targeted against cleavage sites that are homologous between KDR and flt-1 mRNA Because flt-1 and KDR mRNAs are highly homologous in certain regions, some ribozyme target sites are also homologous (see Table X) . In this case, a single ribozyme will target both flt-1 and KDR mRNAs. Hammerhead ribo¬ zyme (FLT/KDR-I) targeted against one of the homologous sites between flt-1 and KDR (flt-1 site 3388 and KDR site 3151) was synthesized as described above. Ribozymes with either a 3 bp stem II or a 4 bp stem II were synthesized. RNA cleavage reactions were carried out in vi tro essentially as described under Example 7. Referring to Figure 16, FLT/KDR-I ribozyme with either a 3 or a 4 bp stem II was able to cleave its target RNA efficiently in vi tro . Example 10: Effect of multiple ribozymes targeted against both flt-1 and KDR RNA on cell proliferation Since both flt-1 and KDR receptors of VEGF are involved in angiogenesis, the inhibition of the expression of both of these genes may be an effective approach to inhibit angiogenesis. Human microvascular endothalial cells were treated with hammerhead ribozymes targeted against sites flt-1 4229 alone, KDR 527 alone, KDR 726 alone, KDR 3950 alone, flt-1 4229 + KDR 527, flt-1 4229 + KDR 726 or flt-1 4229 + KDR 3950. As shown in Figure 17, all the combinations of active ribozymes (A) caused significant inhibition of VEGF-mediated induction of cell proliferation. No significant inhibition of cell proliferation was observed when the cells were treated with a catalytically inactive (I) hammerhead ribozymes. Additionally, cells treated with ribozymes targeted against both flt-1 and KDR RNAs- flt-1 4229 + KDR 527; flt-1 4229 + KDR 726; flt-1 4229 + KDR 3950, were able to cause a greater inhibition of VEGF-mediated induction of cell proliferation when compared with individual ribozymes targeted against either flt-1 or KDR RNA (see flt-1 4229 alone; KDR 527 alone; KDR 726 alone; KDR 3950 alone) . This strongly suggests that treatment of cells with multiple ribozymes may be a more effective means of inhibition of gene expression. Animal Models There are several animal models in which the anti-angiogenesis effect of nucleic acids of the present invention, such as ribozymes, directed against VEGF-R mRNAs can be tested. Typically a corneal model has been used to study angiogenesis in rat and rabbit since recruitment of vessels can easily be followed in this normally avascular tissue (Pandey et al . , 1995 Science 268: 567-569) . In these models, a small Teflon or Hydron disk pretreated with an angiogenesis factor (e.g. bFGF or VEGF) is inserted into a pocket surgically created in the cornea. Angiogenesis is monitored 3 to 5 days later. Ribozymes directed against VEGF-R mRNAs would be delivered in the disk as well, or dropwise to the eye over the time course of the experiment. In another eye model, hypoxia has been shown to cause both increased expression of VEGF and neovascularization in the retina (Pierce et al . , 1995 Proc . Natl . Acad . Sci . USA. 92: 905-909; Shweiki et al . , 1992 J. Clin . Invest . 91: 2235-2243) . In human glioblastomas, it has been shown that VEGF is at least partially responsible for tumor angiogenesis (Plate et al . , 1992 Nature 359, 845) . Animal models have been developed in which glioblastoma cells are implanted subcutaneously into nude mice and the progress of tumor growth and angiogenesism is studied (Kim et al . , 1993 supra; Millauer et al . , 1994 supra) . Another animal model that addresses neovasculariza¬ tion involves Matrigel, an extract of basement membrane that becomes a solid gel when injected subcutaneously (Passaniti et al . , 1992 Lab. Invest . 67: 519-528) . When the Matrigel is supplemented with angiogenesis factors such as VEGF, vessels grow into the Matrigel over a period of 3 to 5 days and angiogenesis can be assessed. Again, ribozymes directed against VEGF-R mRNAs would be delivered in the Matrigel . Several animal models exist for screening of anti- angiogenic agents. These include corneal vessel formation following corneal injury (Burger et al . , 1985 Cornea 4: 35-41; Lepπ, et al . , 1994 J. Ocular Pharmacol . 10: 273- 280; Ormerod et al . , 1990 Am. J. Pathol . 137: 1243-1252) or mtracorneal growth factor implant (Grant et al . , 1993 DiaJ etolog a 36: 282-291; Pandey et al . 1995 supra ; Zieche et al . , 1992 LaJ . Invest. 67: 711-715) , vessel growth into Matrigel matrix containing growth factors (Passaniti et al . , 1992 supra) , female reproductive organ neovasculari- zation following hormonal manipulation (Shweiki et al . , 1993 Clin . Invest . 91: 2235-2243) , several models involv¬ ing inhibition of tumor growth in highly vascularized solid tumors (O'Reilly et al . , 1994 Cell 79: 315-328; Senger et al . , 1993 Cancer and Metas . Rev. 12: 303-324; Takahasi et al . , 1994 Cancer Res . 54: 4233-4237; Kim et al . , 1993 supra) , and transient hypoxia-induced neovascularization m the mouse retina (Pierce et al . , 1995 Proc . Natl . Acad . Sci . USA. 92: 905-909) . The cornea model, described in Pandey et al . supra , is the most common and well characterized anti-angiogenic agent efficacy screening model. This model involves an avascular tissue into which vessels are recruited by a stimulating agent (growth factor, thermal or alkalai burn, endotoxin) . The corneal model would utilize the lntra- stromal corneal implantation of a Teflon pellet soaked m a VEGF-Hydron solution to recruit blood vessels toward the pellet which can be quantitated using standard microscopic and image analysis techniques. To evaluate their anti- angiogenic efficacy, ribozymes are applied topically to the eye or bound within Hydron on the Teflon pellet itself. This avascular cornea as well as the Matrigel (see below) provide for low background assays. While the corneal model has been performed extensively in the rabbit, studies in the rat have also been conducted. The mouse model (Passaniti et al . , supra) is a non-tissue model which utilizes Matrigel, an extract of basement membrane (Kleinman et al . , 1986) or Millipore ® filter disk, which can be impregnated with growth factors and anti-angiogenic agents in a liquid form prior to injection. Upon subcutaneous administration at body temperature, the Matrigel or Millipore ® filter disk forms a solid implant. VEGF embedded in the Matrigel or Millipore ® filter disk would be used to recruit vessels within the matrix of the Matrigel or Millipore ® filter disk which can be processed histologically for endothelial cell specific vWF (factor VIII antigen) immunohisto- chemistry, Trichrome-Masson stain, or hemoglobin content. Like the cornea, the Matrigel or Millipore ® filter disk are avascular; however, it is not tissue. In the Matrigel or Millipore ® filter disk model, ribozymes are adminis¬ tered within the matrix of the Matrigel or Millipore ® filter disk to test their anti-angiogenic efficacy. Thus, delivery issues in this model, as with delivery of ribo¬ zymes by Hydron-coated Teflon pellets in the rat cornea model, may be less problematic due to the homogeneous presence of the ribozyme within the respective matrix. These models offer a distinct advantage over several other angiogenic models listed previously. The ability to use VEGF as a pro-angiogenic stimulus in both models is highly desirable since ribozymes will target only VEGFr mRNA. In other words, the involvement of other non- specific types of stimuli in the cornea and Matrigel models is not advantageous from the standpoint of under¬ standing the pharmacologic mechanism by which the anti-VEGFr mRNA ribozymes produce their effects. In addi¬ tion, the models will allow for testing the specificity of the anti-VEGFr mRNA ribozymes by using either a- or bFGF as a pro-angiogenic factor. Vessel recruitment using FGF should not be affected in either model by anti-VEGFr mRNA ribozymes. Other models of angiogenesis including vessel formation in the female reproductive system using hormonal manipulation (Shweiki et al . , 1993 supra) ; a variety of vascular solid tumor models which involve indirect cor- relations with angiogenesis (O'Reilly et al . , 1994 supra ; Senger et al . , 1993 supra ; Takahasi et al . , 1994 supra ; Kim et al . , 1993 supra) ; and retinal neovascularization following transient hypoxia (Pierce et al . , 1995 supra) were not selected for efficacy screening due to their non-specific nature, although there is a correlation between VEGF and angiogenesis in these models. Other model systems to study tumor angiogenesis is reviewed by Folkman, 1985 Adv. Cancer. Res . . 43, 175. flt-1, KDR and/or flk-1 protein levels can be measured clinically or experimentally by FACS analysis. flt-1, KDR and/or flk-1 encoded mRNA levels will be assessed by Northern analysis, RNase-protection, primer extension analysis and/or quantitative RT-PCR. Ribozymes that block flt-1, KDR and/or flk-1 protein encoding mRNAs and therefore result in decreased levels of flt-1, KDR and/or flk-1 activity by more than 20% in vi tro will be identified. Ribozymes and/or genes encoding them are delivered by either free delivery, liposome delivery, cationic lipid delivery, adeno-associated virus vector delivery, adeno¬ virus vector delivery, retrovirus vector delivery or plasmid vector delivery in these animal model experiments (see above) . Patients can be treated by locally administering nucleic acids targeted against VEGF-R by direct injection. Routes of administration may include, but are not limited to, intravascular, intramuscular, subcutaneous, intra- articular, aerosol inhalation, oral (tablet, capsule or pill form) , topical, systemic, ocular, intraperitoneal and/or intrathecal delivery. Example 11: Ribozvme-mediated inhibition of angiogenesis in vivo The purpose ot this study was to assess the anti- angiogenic activity of hammerhead ribozymes targeted against flt-1 4229 site in the rat cornea model of VEGF induced angiogenesis (see above) . These ribozymes have either active or inactive catalytic core and either bind and cleave or just bind to VEGF-R mRNA of the flt-1 subtype. The active ribozymes, that are able to bind and cleave the target RNA, have been shown to inhibit ( 125 I-labeled) VEGF binding in cultured endothelial cells and produce a dose-dependent decrease in VEGF induced endothelial cell proliferation in these cells (see Examples 3-5 above) . The catalytically inactive forms of these ribozymes, wherein the ribozymes can only bind to the RNA but cannot catalyze RNA cleavage, fail to show these characteristics. The ribozymes and VEGF were co-delivered using the filter disk method: Nitrocellulose filter disks (Millipore ® ) of 0.057 diameter were immersed in appropriate solutions and were surgically implanted in rat cornea as described by Pandey et al . , supra . This delivery method has been shown to deliver rhodamine- labeled free ribozyme to scleral cells and, in all likelihood cells of the pericorneal vascular plexus. Since the active ribozymes show cell culture efficacy and can be delivered to the target site using the disk method, it is essential that these ribozymes be assessed for in vivo anti-angiogenic activity. The stimulus for angiogenesis in this study was the treatment of the filter disk with 30 mM VEGF which is implanted within the cornea's stroma. This dose yields reproducible neovascularization stemming from the peri¬ corneal vascular plexus growing toward the disk in a dose-response study 5 days following implant. Filter disks treated only with the vehicle for VEGF show no angiogenic response. The ribozymes was co-adminstered with VEGF on a disk in two different ribozyme concen- trations. One concern with the simultaneous adminis¬ tration is that the ribozymes will not be able to inhibit angiogenesis since VEGF receptors can be stimulated. However, we have observed that in low VEGF doses, the neovascular response reverts to normal suggesting that the VEGF stimulus is essential for maintaining the angiogenic response. Blocking the production of VEGF receptors using simultaneous administration of anti-VEGF-R mRNA ribozymes could attenuate the normal neovascularization induced by the filter disk treated with VEGF. Materials and Methods: 1. Stock hammerhead ribozyme solutions: a. flt-1 4229 (786 μM) - Active b. flt-1 4229 (736 μM) - Inactive 2. Experimantal solutions/groups: Group 1 Solution 1 Control VEGF solution: 30 μM in 82mM Tris base Group 2 Solution 2 flt-1 4229 (1 μg/μL) in 30 μM VEGF/82 mM Tris base Group 3 Solution 3 flt-1 4229 (10 μg/μL) in 30 μM VEGF/82 mM Tris base Group 4 Solution 4 No VEGF, flt-1 4229 (10 μg/μL) in 82 mM Tris base Group 5 Solution 5 No VEGF, No ribozyme in 82 mM Tris base 10 eyes per group, 5 animals (Since they have similar molecular weights, the molar concentrations should be essentially similar) . Each solution (VEGF and RIBOZYMES) were prepared as a 2X solution for 1:1 mixing for final concentrations above, with the exception of solution 1 in which VEGF was 2X and diluted with ribozyme diluent (sterile water) . 3. VEGF Solutions The 2X VEGF solution (60 μM) was prepared from a stock of 0.82 μg/μL in 50 mM Tris base. 200 μL of VEGF stock was concentrated by speed vac to a final volume of 60.8 μL, for a final concentration of 2.7 μg/μL or 60 μM. Six 10 μL aliquots was prepared for daily mixing. 2X solutions for VEGF and Ribozyme was stored at 4"C until the day of the surgery. Solutions were mixed for each day of surgery. Original 2X solutions was prepared on the day before the first day of the surgery. 4. Surgical Solutions: Anesthesia: stock ketamine hydrochloride 100 mg/mL stock xylazine hydrochloride 20 mg/mL stock acepromazine 10 mg/mL Final anesthesia solution: 50 mg/mL ketamine, 10 mg/mL xylazine, and 0.5 mg/mL acepromazine 5% povidone iodine for opthalmic surgical wash 2% lidocaine (sterile) for opthalmic administration (2 drops per eye) sterile 0.9% NaCl for opthalmic irrigation 5. Surgical Methods : Standard surgical procedure as described in Pandey et al . , supra . Filter disks were incubated in 1 μL of each solution for approximately 30 minutes prior to implantation. 5. Experimental Protocol : The animal cornea were treated with the treatment groups as described above. Animals were allowed to recover for 5 days after treatment with daily observation (scoring 0 - 3) . On the fifth day animals were euthanized and digital images of each eye was obtained for quantitaion using Image Pro Plus. Quantitated neovascular surface area were analyzed by ANOVA followed by two post-hoc tests including Dunnets and Tukey-Kramer tests for significance at the 95% confidence level. Dunnets provide information on the significance between the differences within the means of treatments vs. controls while Tukey-Kramer provide information on the significance of differences within the means of each group. Results are graphically represented in Figure 18. As shown in the figure, flt-1 4229 active hammerhead ribozyme at both concentrations was effective at inhibiting angio¬ genesis while the inactive ribozyme did not show any significant reduction in angiogenesis. A statistically signifiant reduction in neovascular surface area was observed only with active ribozymes. This result clearly shows that the ribozymes are capable of significantly inhibiting angiogenesis in vivo . Specifically, the mechanism of inhibition appears to be by the binding and cleavage of target RNA by ribozymes. Diagnostic uses Ribozymes of this invention may be used as diagnostic tools to examine genetic drift and mutations within diseased cells or to detect the presence of flt-1, KDR and/or flk-1 RNA in a cell. The close relationship between ribozyme activity and the structure of the target RNA allows the detection of mutations in any region of the molecule which alters the base-pairing and three- dimensional structure of the target RNA. By using multiple ribozymes described in this invention, one may map nucleotide changes which are important to RNA structure and function in vi tro, as well as in cells and tissues. Cleavage of target RNAs with ribozymes may be used to inhibit gene expression and define the role (essentially) of specified gene products in the progres¬ sion of disease. In this manner, other genetic targets may be defined as important mediators of the disease. These experiments will lead to better treatment of the disease progression by affording the possibility of combinational therapies ( e . g. , multiple ribozymes targeted to different genes, ribozymes coupled with known small molecule inhibitors, or intermittent treatment with combinations of ribozymes and/or other chemical or biological molecules) . Other in vi tro uses of ribozymes of this invention are well known in the art, and include detection of the presence of mRNAs associated with flt-1, KDR and/or flk-1 related condition. Such RNA is detected by determining the presence of a cleavage product after treatment with a ribozyme using standard methodology. In a specific example, ribozymes which can cleave only wild-type or mutant forms of the target RNA are used for the assay. The first ribozyme is used to identify wild-type RNA present in the sample and the second ribo¬ zyme will be used to identify mutant RNA in the sample. As reaction controls, synthetic substrates of both wild- type and mutant RNA will be cleaved by both ribozymes to demonstrate the relative ribozyme efficiencies in the reactions and the absence of cleavage of the "non- targeted" RNA species. The cleavage products from the synthetic substrates will also serve to generate size markers for the analysis of wild-type and mutant RNAs in the sample population. Thus each analysis will require two ribozymes, two substrates and one unknown sample which will be combined into six reactions. The presence of cleavage products will be determined using an RNAse pro- tection assay so that full-length and cleavage fragments of each RNA can be analyzed in one lane of a polyacryl¬ amide gel. It is not absolutely required to quantify the results to gain insight into the expression of mutant RNAs and putative risk of the desired phenotypic changes in target cells. The expression of mRNA whose protein product is implicated in the development of the phenotype (i.e., flt-1, KDR and/or flk-1) is adequate to establish risk. If probes of comparable specific activity are used for both transcripts, then a qualitative comparison of RNA levels will be adequate and will decrease the cost of the initial diagnosis. Higher mutant form to wild-type ratios will be correlated with higher risk whether RNA levels are compared qualitatively or quantitatively. Other embodiments are within the following claims. Table I Characteristics of Ribozymes Group I Introns Size: -200 to >1000 nucleotides Requires a U in the target sequence immediately 5' of the cleavage site. Binds 4-6 nucleotides at 5' side of cleavage site. Over 75 known members of this class. Found in Tetrahymena thermophila rRNA, fungal mitochondria, chloroplasts, phage T4 , blue-green algae, and others. RNAseP RNA (Ml RNA) Size: -290 to 400 nucleotides RNA portion of a ribonucleoprotein enzyme. Cleaves tRNA precursors to form mature tRNA. Roughly 10 known members of this group all are bacterial in origin. Hammerhead Ribozyme Size: -13 to 40 nucleotides. Requires the target sequence UH immediately 5' of the cleavage site. Binds a variable number of nucleotides on both sides of the cleavage site. 14 known members of this class. Found in a number of plant pathogens (virusoids) that use RNA as the infectious agent (Figure 1 and 2) Hairpin Ribozyme Size: -50 nucleotides. Requires the target sequence GUC immediately 3' of the cleavage site. Binds 4-6 nucleotides at 5' side of the cleavage site and a variable number to the 3' side of the cleavage site. Only 3 known member of this class. Found in three plant pathogen (satellite RNAs of the tobacco ringspot virus, arabis mosaic virus and chicory yellow mottle virus) which uses RNA as the infectious agent (Figure 3) . Hepatitis Delta Virus (HDV) Ribozyme Size: 50-60 nucleotides (at present) Sequence requirements not fully determined. Binding sites and structural requirements not fully determined, although no sequences 5' of cleavage site are required. Only 1 known member of this class. Found in human HDV (Figure 4) . Neurospora VS RNA Ribozyme Size: -144 nucleotides (at present) Cleavage of target RNAs recently demonstrated. Sequence requirements not fully determined. Binding sites and structural requirements not fully determined. Only 1 known member of this class. Found in Neurospora VS RNA (Figure 5) . Table II: Human fltl VEGF Receptor-Hammerhead Ribozyme and Substrate Sequence nt. HH Ribozyme Substrate Posi¬ tion 10 GCCGAGAG CUGAUGA X GAA AGUGUCCG CGGACACUC CUCUCGGC 13 GGAGCCGA CUGAUGA X GAA AGGAGUGU ACACUCCUC UCGGCUCC 15 GAGGAGCC CUGAUGA X GAA AGAGGAGU ACUCCUCUC GGCUCCUC 20 CCGGGGAG CUGAUGA X GAA AGCCGAGA UCUCGGCUC CUCCCCGG 23 CUGCCGGG CUGAUGA X GAA AGGAGCCG CGGCUCCUC CCCGGCAG 43 CCCGCUCC CUGAUGA X GAA AGCCGCCG CGGCGGCUC GGAGCGGG 54 GAGCCCCG CUGAUGA X GAA AGCCCGCU AGCGGGCUC CGGGGCUC 62 CUGCACCC CUGAUGA X GAA AGCCCCGG CCGGGGCUC GGGUGCAG 97 CCCCGGGU CUGAUGA X GAA AUCCUCGC GCGAGGAUU ACCCGGGG 98 UCCCCGGG CUGAUGA X GAA AAUCCUCG CGAGGAUUA CCCGGGGA GAA AUAAAGUC GACUUUAUA CUUGUCGU GAA AGUAUAAA UUUAUACUU GUCGUGUA GAA ACAAGUAU AUACUUGUC GUGUAAGG GAA ACACGACA UGUCGUGUA AGGAGUGG GAA AUGGUCCA UGGACCAUC AUUCAAAU GAA AUGAUGGU ACCAUCAUU CAAAUCUG GAA AAUGAUGG CCAUCAUUC AAAUCUGU GAA AUUUGAAU AUUCAAAUC UGUUAACA GAA ACAGAUUU AAAUCUGUU AACACCUC GAA AACAGAUU AAUCUGUUA ACACCUCA GAA AGGUGUUA UAACACCUC AGUGCAUA GAA AUGCACUG CAGUGCAUA UAUAUGAU GAA AUAUGCAC GUGCAUAUA UAUGAUAA GAA AUAUAUGC GCAUAUAUA UGAUAAAG GAA AUCAUAUA UAUAUGAUA AAGCAUUC GAA AUGCUUUA UAAAGCAUU CAUCACUG GAA AAUGCUUU AAAGCAUUC AUCACUGU GAA AUGAAUGC GCAUUCAUC ACUGUGAA GAA AUGUUUCA UGAAACAUC GAAAACAG GAA AGCACCUG CAGGUGCUU GAAACCGU GAA ACGGUUUC GAAACCGUA GCUGGCAA GAA ACCGCUUG CAAGCGGUC UUACCGGC GAA AGACCGCU AGCGGUCUU ACCGGCUC GAA AAGACCGC GCGGUCUUA CCGGCUCU GAA AGCCGGUA UACCGGCUC UCUAUGAA GAA AGAGCCGG CCGGCUCUC UAUGAAAG GAA AGAGAGCC GGCUCUCUA UGAAAGUG GAA AUGCCUUC GAAGGCAUU UCCCUCGC GAA AAUGCCUU AAGGCAUUU CCCUCGCC GAA AAAUGCCU AGGCAUUUC CCUCGCCG GAA AGGGAAAU AUUUCCCUC GCCGGAAG GAA ACUUCCGG CCGGAAGUU GUAUGGUU GAA ACAACUUC GAAGUUGUA UGGUUAAA GAA AGCCGCUC GAGCGGCUC CCUUAUGA GAA AGGGAGCC GGCUCCCUU AUGAUGCC GAA AAGGGAGC GCUCCCUUA UGAUGCCA GAA ACUCCCAC GUGGGAGUU UGCCCGGG GAA AACUCCCA UGGGAGUUU GCCCGGGA GAA AGUCUCUC GAGAGACUU AAACUGGG GAA AAGUCUCU AGAGACUUA AACUGGGC GAA AUUUGCCC GGGCAAAUC ACUUGGAA GAA AGUGAUUU AAAUCACUU GGAAGAGG GAA AGCCCCUC GAGGGGCUU UUGGAAAA GAA AAGCCCCU AGGGGCUUU UGGAAAAG GAA AAAGCCCC GGGGCUUUU GGAAAAGU GAA ACCACUUU AAAGUGGUU CAAGCAUC GAA AACCACUU AAGUGGUUC AAGCAUCA GAA AUGCUUGA UCAAGCAUC AGCAUUUG GAA AUGCUGAU AUCAGCAUU UGGCAUUA GAA AAUGCUGA UCAGCAUUU GGCAUUAA GAA AUGCCAAA UUUGGCAUU AAGAAAUC GAA AAUGCCAA UUGGCAUUA AGAAAUCA GAA AUUUCUUA UAAGAAAUC ACCUACGU GAA AGGUGAUU AAUCACCUA CGUGCCGG GAA ACUCGCUG CAGCGAGUA CAAAGCUC GAA AGCUUUGU ACAAAGCUC UGAUGACU GAA AGCUCAGU ACUGAGCUA AAAAUCUU GAA AUUUUUAG CUAAAAAUC UUGACCCA GAA AGAUUUUU AAAAAUCUU GACCCACA GAA AUGUGGGU ACCCACAUU GGCCACCA GAA AUGGUGGC GCCACCAUC UGAACGUG GAA ACCACGUU AACGUGGUU AACCUGCU GAA AACCACGU ACGUGGUUA ACCUGCUG GAA AGGCCCUC GAGGGCCUC UGAUGGUG GAA AUCACCAU AUGGUGAUU GUUGAAUA GAA ACAAUCAC GUGAUUGUU GAAUACUG GAA AGGUUUUG CAAAACCUU UGAAGAAC GAA AAGGUUUU AAAACCUUU GAAGAACU GAA AGUUCUUC GAAGAACUU UUACCGAA GAA AAGUUCUU AAGAACUUU UACCGAAU GAA AAAGUUCU AGAACUUUU ACCGAAUG GAA AAAAGUUC GAACUUUUA CCGAAUGC GAA AGGUGGCA UGCCACCUC CAUGUUUG GAA ACAUGGAG CUCCAUGUU UGAUGACU GAA AACAUGGA UCCAUGUUU GAUGACUA GAA AGUCAUCA UGAUGACUA CCAGGGCG GAA AGUGCUGC GCAGCACUC UGUUGGCC GAA ACAGAGUG CACUCUGUU GGCCUCUC GAA AGGCCAAC GUUGGCCUC UCCCAUGC GAA AGAGGCCA UGGCCUCUC CCAUGCUG GAA AGCGCUUC GAAGCGCUU CACCUGGA GAA AAGCGCUU AAGCGCUUC ACCUGGAC GAA AGGCCUUG CAAGGCCUC GCUCAAGA GAA AGCGAGGC GCCUCGCUC AAGAUUGA GAA AUCUUGAG CUCAAGAUU GACUUGAG GAA AGUCAAUC GAUUGACUU GAGAGUAA GAA ACUCUCAA UUGAGAGUA ACCAGUAA GAA ACUGGUUA UAACCAGUA AAAGUAAG GAA ACUUUUAC GUAAAAGUA AGGAGUCG GAA ACUCCUUA UAAGGAGUC GGGGCUGU GAA ACAGCCCC GGGGCUGUC UGAUGUCA GAA ACAUCAGA UCUGAUGUC AGCAGGCC GAA ACUGGGCC GGCCCAGUU UCUGCCAU GAA AACUGGGC GCCCAGUUU CUGCCAUU GAA AAACUGGG CCCAGUUUC UGCCAUUC GAA AUGGCAGA UCUGCCAUU CCAGCUGU GAA AAUGGCAG CUGCCAUUC CAGCUGUG GAA ACGUGCCC GGGCACGUC AGCGAAGG GAA ACCUGCGC GCGCAGGUU CACCUACG GAA AAUACAUA UAUGUAUUU AGGAUGUC GAA AAAUACAU AUGUAUUUA GGAUGUCU GAA ACAUCCUA UAGGAUGUC UGCACCUU GAA AGGUGCAG CUGCACCUU CUGCAGCC GAA AAGGUGCA UGCACCUUC UGCAGCCA GAA ACUGGCUG CAGCCAGUC AGAAGCUG GAA AUCCACUG CAGUGGAUU GCUGCUUC GAA AGCAGCAA UUGCUGCUU CUUGGGGA GAA AAGCAGCA UGCUGCUUC UUGGGGAG GAA AGAAGCAG CUGCUUCUU GGGGAGAA GAA ACUCUUCU AGAAGAGUA UGCUUCCU GAA AGCAUACU AGUAUGCUU CCUUUUAU GAA AAGCAUAC GUAUGCUUC CUUUUAUC GAA AGGAAGCA UGCUUCCUU UUAUCCAU GAA AAGGAAGC GCUUCCUUU UAUCCAUG GAA AAAGGAAG CUUCCUUUU AUCCAUGU GAA AAAAGGAA UUCCUUUUA UCCAUGUA GAA AUAAAAGG CCUUUUAUC CAUGUAAU GAA ACAUGGAU AUCCAUGUA AUUUAACU GAA AUUACAUG CAUGUAAUU UAACUGUA GAA AAUUACAU AUGUAAUUU AACUGUAG GAA AAAUUACA UGUAAUUUA ACUGUAGA GAA ACAGUUAA UUAACUGUA GAACCUGA GAA AGCUCAGG CCUGAGCUC UAAGUAAC GAA AGAGCUCA UGAGCUCUA AGUAACCG GAA ACUUAGAG CUCUAAGUA ACCGAAGA GAA ACAUUCUU AAGAAUGUA UGCCUCUG GAA AGGCAUAC GUAUGCCUC UGUUCUUA GAA ACAGAGGC GCCUCUGUU CUUAUGUG GAA AACAGAGG CCUCUGUUC UUAUGUGC GAA AGAACAGA UCUGUUCUU AUGUGCCA GAA AAGAACAG CUGUUCUUA UGUGCCAC GAA AUGUGGCA UGCCACAUC CUUGUUUA 7662 GGAUGUUU CUGAUGA X GAA AACGGGUU AACCCGUUA AAACAUCC 7669 UGCCACAG CUGAUGA X GAA AUGUUUUA UAAAACAUC CUGUGGCA Where "X" represents stem II region of a HH ribozyme (Hertel et al . , 1992 Nucleic Acids Res . 20 3252) . The length of stem II may be ≥ 2 base-pairs. Table III: Human fltl VEGF Receptor-Hairpin Ribozyme and Substrate Sequence HP Ribozyme Sequence Substrate ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CCUCUCG GCU CCUCCCCG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGCGGCG GCU CGGAGCGG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GAGGACG GAC UCUGGCGG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UCUGGCG GCC GGGUCGUU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGGUCCU GCU GUGCGCGC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GCGCGCU GCU CAGCUGUC V ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CUGCUCA GCU GUCUGCUU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CUCAGCU GUC UGCUUCUC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GCUGUCU GCU UCUCACAG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGAAGCA GCC CAUAAAUG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UAAAUCU GCC UGUGGAAG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GAACACA GCU CAAGCAAA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UUCUACA GCU GCAAAUAU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AUUCCCU GCC GGGUUACG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GAUCCCU GAU GGAAAACG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGCUUCU GAC CUGUGAAG 1056 UUUUUUUC AGAA GGGUAA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UUACCCU GAU GAAAAAAA 1301 GCCGGUAA AGAA GCUUGC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GCAAGCG GUC UUACCGGC 1310 UCAUAGAG AGAA GGUAAG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CUUACCG GCU CUCUAUGA 1389 AAAUAGCG AGAA GAUUUC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GAAAUCU GCU CGCUAUUU 5 1535 UUUCGUAA AGAA GGGGUU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AACCCCA GAU UUACGAAA 1566 AGAGCCGG AGAA GGAAAC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GUUUCCA GAC CCGGCUCU 1572 GGGUAGAG AGAA GGGUCU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AGACCCG GCU CUCUACCC 1604 CGGUACAA AGAA GGAUUU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AAAUCCU GAC UUGUACCG 1824 AUUCUAGA AGAA GCCACA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UGUGGCU GAC UCUAGAAU 10 1908 UUUGGCAC AGAA GUGAUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UAUCACA GAU GUGCCAAA 1949 CUCCUUCC AGAA GCAUUU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AAAUGCC GAC GGAAGGAG 1973 CUGUGCAA AGAA GUUUCA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UGAAACU GUC UUGCACAG 2275 AGUGGUGG AGAA GCUGAU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AUCAGCA GUU CCACCACU 2321 ACCAAGUG AGAA GAGGCU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AGCCUCA GAU CACUUGGU 15 2396 UUUCAAUA AGAA GCGUGC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GCACGCU GUU UAUUGAAA 2490 GUUCCUUG AGAA GUGAGG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CCUCACU GUU CAAGGAAC 2525 UUAGAGUG AGAA GCUCCA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UGGAGCU GAU CACUCUAA 2625 GAUAGGUA AGAA GUCUUU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AAAGACU GAC UACCUAUC 2652 GGAACUUC AGAA GGGUCC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGACCCA GAU GAAGUUCC 2684 CAUAAGGG AGAA GCUCAC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 2816 CAGCCACA AGAA GGCACG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 2873 GCUCAGUC AGAA GAGCUU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 2930 AGGCUCCC AGAA GGUUAA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 5 2963 CAAUCACC AGAA GAGGCC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 3157 UUCCUGAA AGAA GGAGCU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 3207 UAGAAACC AGAA GAAUCC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 3211 CUUGUAGA AGAA GUCAGA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 3245 UGUAAGAA AGAA GAUCUU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 10 3256 CACUUGAA AGAA GUAAGA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 3287 UUCUGGAA AGAA GGAACU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 3402 CUCACAUA AGAA GGGUUC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 3580 CCUCAGGC AGAA GCAAAA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 3641 CCAGCAUG AGAA GAUAGA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 15 3655 UCUGUGCC AGAA GUCCAG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 3810 UCAGAGAA AGAA GGAGUU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 3846 AACUUCGG AGAA GAAAUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 3873 CUGACAUC AGAA GAGCUU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 3995 GAGAGGCC AGAA GAGUGC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 5319 UUUCCUCC AGAA GCCCUC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 5358 GGUAUAGA AGAA GGGUCU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 5392 UGGGUCCC AGAA GUGUUG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 5563 UGAGUCCC AGAA GGAGAA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 5 5622 AGUUUCAA AGAA GUUGAA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 5738 UAGCAUCA AGAA GAGCCA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 5838 UAGCAUCA AGAA GAGCCA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 5933 CCCCAAGA AGAA GCAAUC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 6022 CACAUAAG AGAA GAGGCA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 10 6120 UCCACAAA AGAA GCUGCC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 6163 GUGGAGAG AGAA GUCCCA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 6270 AAAUUGCC AGAA GUCACA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 6 12 AAGACAUG AGAA GCUAAG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 6511 UUUGAAGG AGAA GAGUAA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 15 6778 UCCACCCA AGAA GUUCCA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 6826 ACUUCUUG AGAA GACAAG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 7245 AACAUAAA AGAA GUUGCC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 7258 UGGAAGGA AGAA GAACAU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 7433 CCCAUACA AGAA GCUAAA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 7512 UUUUCAUG AGAA GGAAUU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AAUUCCU GUC CAUGAAAA 7606 GACAUUCA AGAA GAAAUG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CAUUUCA GCC UGAAUGUC 7618 AAUAUAUA AGAA GACAUU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AAUGUCU GCC UAUAUAUU 7633 AUACAAAG AGAA GAGAAU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AUUCUCU GCU CUUUGUAU ble IV: Human KDR VEGF Rece tor-Hammerh GAA AAAUGGAG CUCCAUUUA UUGCUUCU GAA AUAAAUGG CCAUUUAUU GCUUCUGU GAA AGCAAUAA UUAUUGCUU CUGUUAGU GAA AAGCAAUA UAUUGCUUC UGUUAGUG GAA ACAGAAGC GCUUCUGUU AGUGACCA GAA AACAGAAG CUUCUGUUA GUGACCAA GAA ACUCCAUG CAUGGAGUC GUGUACAU GAA ACACGACU AGUCGUGUA CAUUACUG GAA AUGUACAC GUGUACAUU ACUGAGAA GAA AAUGUACA UGUACAUUA CUGAGAAC GAA AUCACCAC GUGGUGAUU CCAUGUCU GAA AAUCACCA UGGUGAUUC CAUGUCUC GAA ACAUGGAA UUCCAUGUC UCGGGUCC GAA AGACAUGG CCAUGUCUC GGGUCCAU GAA ACCCGAGA UCUCGGGUC CAUUUCAA GAA AUGGACCC GGGUCCAUU UCAAAUCU GAA AAUGGACC GGUCCAUUU CAAAUCUC GAA AAAUGGAC GUCCAUUUC AAAUCUCA GAA AUUUGAAA UUUCAAAUC UCAACGUG GAA AGAUUUGA UCAAAUCUC AACGUGUC GAA ACACGUUG CAACGUGUC ACUUUGUG GAA AGUGACAC GUGUCACUU UGUGCAAG GAA AAGUGACA UGUCACUUU GUGCAAGA GAA AUCUUGCA UGCAAGAUA CCCAGAAA GAA AUCUCUUU AAAGAGAUU UGUUCCUG GAA AAUCUCUU AAGAGAUUU GUUCCUGA GAA ACAAAUCU AGAUUUGUU CCUGAUGG GAA AACAAAUC GAUUUGUUC CUGAUGGU GAA ACCAUCAG CUGAUGGUA ACAGAAUU GAA AUUCUGUU AACAGAAUU UCCUGGGA GAA AAUUCUGU ACAGAAUUU CCUGGGAC GAA AAAUUCUG CAGAAUUUC CUGGGACA GAA AGCCCUUC GAAGGGCUU UACUAUUC 4174 CUGUUGUC CUGAUGA X GAA AAAUGAAA UUUCAUUUC GACAACAG 4194 UGCAGUCC CUGAUGA X GAA AGGUCCUU AAGGACCUC GGACUGCA 4214 GCCUAGAA CUGAUGA X GAA AGCUGGCU AGCCAGCUC UUCUAGGC 4216 AAGCCUAG CUGAUGA X GAA AGAGCUGG CCAGCUCUU CUAGGCUU 4217 CAAGCCUA CUGAUGA X GAA AAGAGCUG CAGCUCUUC UAGGCUUG 4219 CACAAGCC CUGAUGA X GAA AGAAGAGC GCUCUUCUA GGCUUGUG Where "X" represents stem II region of a HH ribozyme (Hertel et al . , 1992 Nucleic Acids Res . 20 3252) . The length of stem II may be ≥ 2 base-pairs. Table V: Human KDR VEGF Receptor-Hairpin Ribozyme and Substrate Sequences irpin Ribozyme Sequence Substrate ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AGGUGCU GCU GGCCGUCG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GCUGGCC GUC GCCCUGUG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CCGGGCC GCC UCUGUGGG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UUGAUCU GCC CAGGCUCA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGAAACU GAC UUGGCCUC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GAUUACA GAU CUCCAUUU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UGUUCCU GAU GGUAACAG C ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GUUACCA GUC UAUUAUGU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UGAGUCC GUC UCAUGGAA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACUAUCU GUU GGAGAAAA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AAACCCA GUC UGGGAGUG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GUGGGCU GAU GACCAAGA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AUGUACU GAC GAUUAUGG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CACCCCA GAU UGGUGAGA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AUGUACG GUC UAUGCCAU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AUUGGCA GUU GGAGGAAG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CCAAGCU GUC UCAGUGAC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UGUGUCA GCU UUGUACAA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ' ACAUGCA GCC CACUGAGC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GCAGACA GAU CUACGUUU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GCCCACA GCC UCUGCCAA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CACACCU GUU UGCAAGAA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UAUGUCU GCC UUGCUCAA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UCAGGCA GCU CACAGUCC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GCUCACA GUC CUAGAGCG VO ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AGAAUCA GAC GACAAGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CUCCACA GAU CAUGUGGU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGAUCCA GAU GAACUCCC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AACGACU GCC UUAUGAUG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GAGACCG GCU GAACCUAG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UGAAGCA GAU GCCUUUGG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GAAACCU GUC CACUUACC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UCAGCCA GCU CUGGAUUU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACUUCCU GAC CUUGGAGC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UGUUACA GCU UCCAAGUG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AGAUCCA GAU UAUGUCAG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGCCCCU GAU UAUACUAC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UGUACCA GAC CAUGCUGG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CUGGACU GCU GGCACGGG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UCUCUCU GCC UACCUCAC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CUCACCU GUU UCCUGUAU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AGAGCCG GCC UGUGAGUG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AAUCCCA GAU GACAACCA o ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACAACCA GAC GGACAGUG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GCUACCA GUC CGGAUAUC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UCACUCC GAU GACACAGA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UAGCACA GCC CAGAUUCU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CAGCCCA GAU UCUCCAGC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UUCUCCA GCC UGACACGG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UCCUCCU GUU UAAAAGGA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GAGGUCU GCU CAGAUUUU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CUGCUCA GAU UUUGAAGU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GACCUCG GAC UGCAGGGA 4210 CCUAGAAG AGAA GGCUCC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGAGCCA GCU CUUCUAGG Table VI: Mouse flk- 1 VEGF Receptor-Hammerhead Ribozyme and Substrate Sequence nt . HH Ribozyme Sequence Substrate Posi tion 13 CCGUACCC CUGAUGA X GAA AUUCGCCC GGGCGAAUU GGGUACGG 18 GGGUCCCG CUGAUGA X GAA ACCCAAUU AAUUGGGUA CGGGACCC 31 UCGACCUC CUGAUGA X GAA AGGGGGGU ACCCCCCUC GAGGUCGA 37 AUACCGUC CUGAUGA X GAA ACCUCGAG CUCGAGGUC GACGGUAU 44 CUUAUCGA CUGAUGA X GAA ACCGUCGA UCGACGGUA UCGAUAAG 46 AGCUUAUC CUGAUGA X GAA AUACCGUC GACGGUAUC GAUAAGCU 50 AUCAAGCU CUGAUGA X GAA AUCGAUAC GUAUCGAUA AGCUUGAU 55 UCGAUAUC CUGAUGA X GAA AGCUUAUC GAUAAGCUU GAUAUCGA 59 GAAUUCGA CUGAUGA X GAA AUCAAGCU AGCUUGAUA UCGAAUUC 61 CCGAAUUC CUGAUGA X GAA AUAUCAAG CUUGAUAUC GAAUUCGG 66 UGGGCCCG CUGAUGA X GAA AUUCGAUA UAUCGAAUU CGGGCCCA 67 CUGGGCCC CUGAUGA X GAA AAUUCGAU AUCGAAUUC GGGCCCAG 83 GGCUGCGG CUGAUGA X GAA ACACAGUC GACUGUGUC CCGCAGCC 97 AGCCAGGU CUGAUGA X GAA AUCCCGGC GCCGGGAUA ACCUGGCU 114 GUCCGCGG CUGAUGA X GAA AUCGGGUC GACCCGAUU CCGCGGAC 115 UGUCCGCG CUGAUGA X GAA AAUCGGGU ACCCGAUUC CGCGGACA 169 ACCGGGGA CUGAUGA X GAA AGCGCGGG CCCGCGCUC UCCCCGGU 171 AGACCGGG CUGAUGA X GAA AGAGCGCG CGCGCUCUC CCCGGUCU 178 CAGCGCAA CUGAUGA X GAA ACCGGGGA UCCCCGGUC UUGCGCUG 180 CGCAGCGC CUGAUGA X GAA AGACCGGG CCCGGUCUU GCGCUGCG 197 AGAGGCGG CUGAUGA X GAA AUGGCCCC GGGGCCAUA CCGCCUCU 204 AAGUCACA CUGAUGA X GAA AGGCGGUA UACCGCCUC UGUGACUU 212 CCGCAAAG CUGAUGA X GAA AGUCACAG CUGUGACUU CUUUGCGG 213 CCCGCAAA CUGAUGA X GAA AAGUCACA UGUGACUUC UUUGCGGG 215 GGCCCGCA CUGAUGA X GAA AGAAGUCA UGACUUCUU UGCGGGCC 484 AUCACGCU CUGAUGA X GAA AGCAUUGG CCAAUGCUC AGCGUGAU 493 UUCCUCAG CUGAUGA X GAA AUCACGCU AGCGUGAUU CUGAGGAA 494 UUUCCUCA CUGAUGA X GAA AAUCACGC GCGUGAUUC UGAGGAAA 507 GUCACCAA CUGAUGA X GAA ACCCUUUC GAAAGGGUA UUGGUGAC 509 CAGUCACC CUGAUGA X GAA AUACCCUU AAGGGUAUU GGUGACUG 538 GCAGAAGA CUGAUGA X GAA ACUGUCAC GUGACAGUA UCUUCUGC 540 UUGCAGAA CUGAUGA X GAA AUACUGUC GACAGUAUC UUCUGCAA 542 UUUUGCAG CUGAUGA X GAA AGAUACUG CAGUAUCUU CUGCAAAA 543 GUUUUGCA CUGAUGA X GAA AAGAUACU AGUAUCUUC UGCAAAAC 555 GGAAUGGU CUGAUGA X GAA AGUGUUUU AAAACACUC ACCAUUCC 561 ACCCUGGG CUGAUGA X GAA AUGGUGAG CUCACCAUU CCCAGGGU 562 CACCCUGG CUGAUGA X GAA AAUGGUGA UCACCAUUC CCAGGGUG 573 UCAUUUCC CUGAUGA X GAA ACCACCCU AGGGUGGUU GGAAAUGA 583 GGCUCCAG CUGAUGA X GAA AUCAUUUC GAAAUGAUA CUGGAGCC 593 AGCACUUG CUGAUGA X GAA AGGCUCCA UGGAGCCUA CAAGUGCU 602 CCCGGUAC CUGAUGA X GAA AGCACUUG CAAGUGCUC GUACCGGG 605 CGUCCCGG CUGAUGA X GAA ACGAGCAC GUGCUCGUA CCGGGACG 615 GCUAUGUC CUGAUGA X GAA ACGUCCCG CGGGACGUC GACAUAGC 621 GUGGAGGC CUGAUGA X GAA AUGUCGAC GUCGACAUA GCCUCCAC 626 AAACAGUG CUGAUGA X GAA AGGCUAUG CAUAGCCUC CACUGUUU 633 UAGACAUA CUGAUGA X GAA ACAGUGGA UCCACUGUU UAUGUCUA 634 AUAGACAU CUGAUGA X GAA AACAGUGG CCACUGUUU AUGUCUAU 635 CAUAGACA CUGAUGA X GAA AAACAGUG CACUGUUUA UGUCUAUG 639 CGAACAUA CUGAUGA X GAA ACAUAAAC GUUUAUGUC UAUGUUCG 641 CUCGAACA CUGAUGA X GAA AGACAUAA UUAUGUCUA UGUUCGAG 645 UAAUCUCG CUGAUGA X GAA ACAUAGAC GUCUAUGUU CGAGAUUA 646 GUAAUCUC CUGAUGA X GAA AACAUAGA UCUAUGUUC GAGAUUAC 652 UGAUCUGU CUGAUGA X GAA AUCUCGAA UUCGAGAUU ACAGAUCA 653 GUGAUCUG CUGAUGA X GAA AAUCUCGA UCGAGAUUA CAGAUCAC 659 UGAAUGGU CUGAUGA X GAA AUCUGUAA UUACAGAUC ACCAUUCA 665 AGGCGAUG CUGAUGA X GAA AUGGUGAU AUCACCAUU CAUCGCCU 666 GAGGCGAU CUGAUGA X GAA AAUGGUGA UCACCAUUC AUCGCCUC 669 ACAGAGGC CUGAUGA X GAA AUGAAUGG CCAUUCAUC GCCUCUGU 674 CACUGACA CUGAUGA X GAA AGGCGAUG CAUCGCCUC UGUCAGUG 678 UGGUCACU CUGAUGA X GAA ACAGAGGC GCCUCUGUC AGUGACCA 696 AUGUACAC CUGAUGA X GAA AUGCCAUG CAUGGCAUC GUGUACAU 701 CGGUGAUG CUGAUGA X GAA ACACGAUG CAUCGUGUA CAUCACCG 705 UUCUCGGU CUGAUGA X GAA AUGUACAC GUGUACAUC ACCGAGAA 735 CGGCAGGG CUGAUGA X GAA AUCACCAC GUGGUGAUC CCCUGCCG 749 UUGAAAUC CUGAUGA X GAA ACCCUCGG CCGAGGGUC GAUUUCAA 753 AGGUUUGA CUGAUGA X GAA AUCGACCC GGGUCGAUU UCAAACCU 754 GAGGUUUG CUGAUGA X GAA AAUCGACC GGUCGAUUU CAAACCUC 755 UGAGGUUU CUGAUGA X GAA AAAUCGAC GUCGAUUUC AAACCUCA 762 GACACAUU CUGAUGA X GAA AGGUUUGA UCAAACCUC AAUGUGUC 770 CGCAAAGA CUGAUGA X GAA ACACAUUG CAAUGUGUC UCUUUGCG 772 AGCGCAAA CUGAUGA X GAA AGACACAU AUGUGUCUC UUUGCGCU 774 CUAGCGCA CUGAUGA X GAA AGAGACAC GUGUCUCUU UGCGCUAG 775 CCUAGCGC CUGAUGA X GAA AAGAGACA UGUCUCUUU GCGCUAGG 781 UGGAUACC CUGAUGA X GAA AGCGCAAA UUUGCGCUA GGUAUCCA 785 UUUCUGGA CUGAUGA X GAA ACCUAGCG CGCUAGGUA UCCAGAAA 787 CUUUUCUG CUGAUGA X GAA AUACCUAG CUAGGUAUC CAGAAAAG 800 CCGGAACA CUGAUGA X GAA AUCUCUUU AAAGAGAUU UGUUCCGG 801 UCCGGAAC CUGAUGA X GAA AAUCUCUU AAGAGAUUU GUUCCGGA 804 CCAUCCGG CUGAUGA X GAA ACAAAUCU AGAUUUGUU CCGGAUGG 805 UCCAUCCG CUGAUGA X GAA AACAAAUC GAUUUGUUC CGGAUGGA 822 UCCCAGGA CUGAUGA X GAA AUUCUGUU AACAGAAUU UCCUGGGA 823 GUCCCAGG CUGAUGA X GAA AAUUCUGU ACAGAAUUU CCUGGGAC 824 UGUCCCAG CUGAUGA X GAA AAAUUCUG CAGAAUUUC CUGGGACA 840 GUAAAGCC CUGAUGA X GAA AUCUCGCU AGCGAGAUA GGCUUUAC 845 GGAGAGUA CUGAUGA X GAA AGCCUAUC GAUAGGCUU UACUCUCC 846 GGGAGAGU CUGAUGA X GAA AAGCCUAU AUAGGCUUU ACUCUCCC 847 GGGGAGAG CUGAUGA X GAA AAAGCCUA UAGGCUUUA CUCUCCCC 850 ACUGGGGA CUGAUGA X GAA AGUAAAGC GCUUUACUC UCCCCAGU 852 UAACUGGG CUGAUGA X GAA AGAGUAAA UUUACUCUC CCCAGUUA 859 GAUCAUGU CUGAUGA X GAA ACUGGGGA UCCCCAGUU ACAUGAUC 860 UGAUCAUG CUGAUGA X GAA AACUGGGG CCCCAGUUA CAUGAUCA 867 GCAUAGCU CUGAUGA X GAA AUCAUGUA UACAUGAUC AGCUAUGC 872 UGCCGGCA CUGAUGA X GAA AGCUGAUC GAUCAGCUA UGCCGGCA 885 UCACAGAA CUGAUGA X GAA ACCAUGCC GGCAUGGUC UUCUGUGA 887 CCUCACAG CUGAUGA X GAA AGACCAUG CAUGGUCUU CUGUGAGG 888 GCCUCACA CUGAUGA X GAA AAGACCAU AUGGUCUUC UGUGAGGC 903 UCAUCAUU CUGAUGA X GAA AUCUUUGC GCAAAGAUC AAUGAUGA 917 UAGACUGA CUGAUGA X GAA AGGUUUCA UGAAACCUA UCAGUCUA 919 GAUAGACU CUGAUGA X GAA AUAGGUUU AAACCUAUC AGUCUAUC 923 ACAUGAUA CUGAUGA X GAA ACUGAUAG CUAUCAGUC UAUCAUGU 925 GUACAUGA CUGAUGA X GAA AGACUGAU AUCAGUCUA UCAUGUAC 927 AUGUACAU CUGAUGA X GAA AUAGACUG CAGUCUAUC AUGUACAU 932 CAACUAUG CUGAUGA X GAA ACAUGAUA UAUCAUGUA CAUAGUUG 936 ACCACAAC CUGAUGA X GAA AUGUACAU AUGUACAUA GUUGUGGU 939 ACAACCAC CUGAUGA X GAA ACUAUGUA UACAUAGUU GUGGUUGU 945 UAUCCUAC CUGAUGA X GAA ACCACAAC GUUGUGGUU GUAGGAUA 948 CUAUAUCC CUGAUGA X GAA ACAACCAC GUGGUUGUA GGAUAUAG 953 AAAUCCUA CUGAUGA X GAA AUCCUACA UGUAGGAUA UAGGAUUU 955 AUAAAUCC CUGAUGA X GAA AUAUCCUA UAGGAUAUA GGAUUUAU 960 ACAUCAUA CUGAUGA X GAA AUCCUAUA UAUAGGAUU UAUGAUGU 961 CACAUCAU CUGAUGA X GAA AAUCCUAU AUAGGAUUU AUGAUGUG 962 UCACAUCA CUGAUGA X GAA AAAUCCUA UAGGAUUUA UGAUGUGA 972 GGGCUCAG CUGAUGA X GAA AUCACAUC GAUGUGAUU CUGAGCCC 973 GGGGCUCA CUGAUGA X GAA AAUCACAU AUGUGAUUC UGAGCCCC 993 GAUAGCUC CUGAUGA X GAA AUUUCAUG CAUGAAAUU GAGCUAUC 999 CCGGCAGA CUGAUGA X GAA AGCUCAAU AUUGAGCUA UCUGCCGG 1001 CUCCGGCA CUGAUGA X GAA AUAGCUCA UGAGCUAUC UGCCGGAG 1017 UUUAAGAC CUGAUGA X GAA AGUUUUUC GAAAAACUU GUCUUAAA 1020 CAAUUUAA CUGAUGA X GAA ACAAGUUU AAACUUGUC UUAAAUUG 1022 UACAAUUU CUGAUGA X GAA AGACAAGU ACUUGUCUU AAAUUGUA 1023 GUACAAUU CUGAUGA X GAA AAGACAAG CUUGUCUUA AAUUGUAC 1027 CGCUGUAC CUGAUGA X GAA AUUUAAGA UCUUAAAUU GUACAGCG 1030 UCUCGCUG CUGAUGA X GAA ACAAUUUA UAAAUUGUA CAGCGAGA 1047 CCCACAUU CUGAUGA X GAA AGCUCUGU ACAGAGCUC AAUGUGGG 1059 GUGAAAUC CUGAUGA X GAA AGCCCCAC GUGGGGCUU GAUUUCAC 1063 CCAGGUGA CUGAUGA X GAA AUCAAGCC GGCUUGAUU UCACCUGG 1064 GCCAGGUG CUGAUGA X GAA AAUCAAGC GCUUGAUUU CACCUGGC 1065 UGCCAGGU CUGAUGA X GAA AAAUCAAG CUUGAUUUC ACCUGGCA 1076 AAGGUGGA CUGAUGA X GAA AGUGCCAG CUGGCACUC UCCACCUU 1078 UGAAGGUG CUGAUGA X GAA AGAGUGCC GGCACUCUC CACCUUCA 1084 AGACUUUG CUGAUGA X GAA AGGUGGAG CUCCACCUU CAAAGUCU 1085 GAGACUUU CUGAUGA X GAA AAGGUGGA UCCACCUUC AAAGUCUC 1091 UAUGAUGA CUGAUGA X GAA ACUUUGAA UUCAAAGUC UCAUCAUA 1093 CUUAUGAU CUGAUGA X GAA AGACUUUG CAAAGUCUC AUCAUAAG 1096 CUUCUUAU CUGAUGA X GAA AUGAGACU AGUCUCAUC AUAAGAAG 1099 AAUCUUCU CUGAUGA X GAA AUGAUGAG CUCAUCAUA AGAAGAUU 1107 CGGUUUAC CUGAUGA X GAA AUCUUCUU AAGAAGAUU GUAAACCG 1110 UCCCGGUU CUGAUGA X GAA ACAAUCUU AAGAUUGUA AACCGGGA 1130 UCCCAGGA CUGAUGA X GAA AGGGUUUC GAAACCCUU UCCUGGGA 1131 GUCCCAGG CUGAUGA X GAA AAGGGUUU AAACCCUUU CCUGGGAC 1132 AGUCCCAG CUGAUGA X GAA AAAGGGUU AACCCUUUC CUGGGACU 1154 UGCUCAAA CUGAUGA X GAA ACAUCUUC GAAGAUGUU UUUGAGCA 1155 GUGCUCAA CUGAUGA X GAA AACAUCUU AAGAUGUUU UUGAGCAC 1156 GGUGCUCA CUGAUGA X GAA AAACAUCU AGAUGUUUU UGAGCACC 1157 AGGUGCUC CUGAUGA X GAA AAAACAUC GAUGUUUUU GAGCACCU 1166 CUAUUGUC CUGAUGA X GAA AGGUGCUC GAGCACCUU GACAAUAG 1173 ACACUUUC CUGAUGA X GAA AUUGUCAA UUGACAAUA GAAAGUGU 1205 CACAGGUG CUGAUGA X GAA AUUCCCCU AGGGGAAUA CACCUGUG 1215 CUGGACGC CUGAUGA X GAA ACACAGGU ACCUGUGUA GCGUCCAG 1220 GUCCACUG CUGAUGA X GAA ACGCUACA UGUAGCGUC CAGUGGAC 1236 UUUCUCUU CUGAUGA X GAA AUCAUCCG CGGAUGAUC AAGAGAAA 1246 AAAUGUUC CUGAUGA X GAA AUUUCUCU AGAGAAAUA GAACAUUU 1253 CUCGGACA CUGAUGA X GAA AUGUUCUA UAGAACAUU UGUCCGAG 1254 ACUCGGAC CUGAUGA X GAA AAUGUUCU AGAACAUUU GUCCGAGU 1257 UGAACUCG CUGAUGA X GAA ACAAAUGU ACAUUUGUC CGAGUUCA 1263 UUUGUGUG CUGAUGA X GAA ACUCGGAC GUCCGAGUU CACACAAA 1264 CUUUGUGU CUGAUGA X GAA AACUCGGA UCCGAGUUC ACACAAAG 1276 AGCAAUAA CUGAUGA X GAA AGGCUUUG CAAAGCCUU UUAUUGCU 1277 AAGCAAUA CUGAUGA X GAA AAGGCUUU AAAGCCUUU UAUUGCUU 1278 AAAGCAAU CUGAUGA X GAA AAAGGCUU AAGCCUUUU AUUGCUUU 1279 GAAAGCAA CUGAUGA X GAA AAAAGGCU AGCCUUUUA UUGCUUUC 1281 CCGAAAGC CUGAUGA X GAA AUAAAAGG CCUUUUAUU GCUUUCGG 1285 ACUACCGA CUGAUGA X GAA AGCAAUAA UUAUUGCUU UCGGUAGU 1286 CACUACCG CUGAUGA X GAA AAGCAAUA UAUUGCUUU CGGUAGUG 1287 CCACUACC CUGAUGA X GAA AAAGCAAU AUUGCUUUC GGUAGUGG 1291 CAUCCCAC CUGAUGA X GAA ACCGAAAG CUUUCGGUA GUGGGAUG 1304 CCACCAAA CUGAUGA X GAA AUUUCAUC GAUGAAAUC UUUGGUGG 1306 UUCCACCA CUGAUGA X GAA AGAUUUCA UGAAAUCUU UGGUGGAA 1307 CUUCCACC CUGAUGA X GAA AAGAUUUC GAAAUCUUU GGUGGAAG 1330 UCGGACUU CUGAUGA X GAA ACUGCCCA UGGGCAGUC AAGUCCGA 1335 GGGAUUCG CUGAUGA X GAA ACUUGACU AGUCAAGUC CGAAUCCC 1341 UUCACAGG CUGAUGA X GAA AUUCGGAC GUCCGAAUC CCUGUGAA 1352 AACUGAGA CUGAUGA X GAA ACUUCACA UGUGAAGUA UCUCAGUU 1354 GUAACUGA CUGAUGA X GAA AUACUUCA UGAAGUAUC UCAGUUAC 1356 GGGUAACU CUGAUGA X GAA AGAUACUU AAGUAUCUC AGUUACCC 1360 AGCUGGGU CUGAUGA X GAA ACUGAGAU AUCUCAGUU ACCCAGCU 1361 GAGCUGGG CUGAUGA X GAA AACUGAGA UCUCAGUUA CCCAGCUC 1369 GAUAUCAG CUGAUGA X GAA AGCUGGGU ACCCAGCUC CUGAUAUC 1375 CCAUUUGA CUGAUGA X GAA AUCAGGAG CUCCUGAUA UCAAAUGG 1377 UACCAUUU CUGAUGA X GAA AUAUCAGG CCUGAUAUC AAAUGGUA 1385 CAUUUCUG CUGAUGA X GAA ACCAUUUG CAAAUGGUA CAGAAAUG 1404 UUGGACUC CUGAUGA X GAA AUGGGCCU AGGCCCAUU GAGUCCAA 1409 UGUAGUUG CUGAUGA X GAA ACUCAAUG CAUUGAGUC CAACUACA 1415 UCAUUGUG CUGAUGA X GAA AGUUGGAC GUCCAACUA CACAAUGA 1425 UCGCCAAC CUGAUGA X GAA AUCAUUGU ACAAUGAUU GUUGGCGA 1428 UCAUCGCC CUGAUGA X GAA ACAAUCAU AUGAUUGUU GGCGAUGA 1440 AUGAUGGU CUGAUGA X GAA AGUUCAUC GAUGAACUC ACCAUCAU 1446 ACUUCCAU CUGAUGA X GAA AUGGUGAG CUCACCAUC AUGGAAGU 1478 UGACCGUG CUGAUGA X GAA AGUUUCCU AGGAAACUA CACGGUCA 1485 GUGAGGAU CUGAUGA X GAA ACCGUGUA UACACGGUC AUCCUCAC 1 88 UUGGUGAG CUGAUGA X GAA AUGACCGU ACGGUCAUC CUCACCAA 1491 GGGUUGGU CUGAUGA X GAA AGGAUGAC GUCAUCCUC ACCAACCC 1503 UCCAUUGA CUGAUGA X GAA AUGGGGUU AACCCCAUU UCAAUGGA 1504 CUCCAUUG CUGAUGA X GAA AAUGGGGU ACCCCAUUU CAAUGGAG 1505 UCUCCAUU CUGAUGA X GAA AAAUGGGG CCCCAUUUC AAUGGAGA 1530 ACCAGAGA CUGAUGA X GAA ACCAUGUG CACAUGGUC UCUCUGGU 1532 CAACCAGA CUGAUGA X GAA AGACCAUG CAUGGUCUC UCUGGUUG 1534 CACAACCA CUGAUGA X GAA AGAGACCA UGGUCUCUC UGGUUGUG 1539 ACAUUCAC CUGAUGA X GAA ACCAGAGA UCUCUGGUU GUGAAUGU 1548 UGGGGUGG CUGAUGA X GAA ACAUUCAC GUGAAUGUC CCACCCCA 1560 UUCUCACC CUGAUGA X GAA AUCUGGGG CCCCAGAUC GGUGAGAA 1574 GCGAGAUC CUGAUGA X GAA AGGCUUUC GAAAGCCUU GAUCUCGC 1578 AUAGGCGA CUGAUGA X GAA AUCAAGGC GCCUUGAUC UCGCCUAU 1580 CCAUAGGC CUGAUGA X GAA AGAUCAAG CUUGAUCUC GCCUAUGG 1585 GGAAUCCA CUGAUGA X GAA AGGCGAGA UCUCGCCUA UGGAUUCC 1591 CUGGUAGG CUGAUGA X GAA AUCCAUAG CUAUGGAUU CCUACCAG 1592 ACUGGUAG CUGAUGA X GAA AAUCCAUA UAUGGAUUC CUACCAGU 1595 CAUACUGG CUGAUGA X GAA AGGAAUCC GGAUUCCUA CCAGUAUG 1601 UGGUCCCA CUGAUGA X GAA ACUGGUAG CUACCAGUA UGGGACCA 1619 UGCAUGUC CUGAUGA X GAA AUGUCUGC GCAGACAUU GACAUGCA 1632 UUGGCGUA CUGAUGA X GAA ACUGUGCA UGCACAGUC UACGCCAA 1634 GGUUGGCG CUGAUGA X GAA AGACUGUG CACAGUCUA CGCCAACC 1645 GUGCAGGG CUGAUGA X GAA AGGGUUGG CCAACCCUC CCCUGCAC 1659 UACCACUG CUGAUGA X GAA AUGUGGUG CACCACAUC CAGUGGUA 1667 GCUGCCAG CUGAUGA X GAA ACCACUGG CCAGUGGUA CUGGCAGC 1677 GCUUCUUC CUGAUGA X GAA AGCUGCCA UGGCAGCUA GAAGAAGC 1691 GUCUGUAG CUGAUGA X GAA AGCAGGCU AGCCUGCUC CUACAGAC 1694 CGGGUCUG CUGAUGA X GAA AGGAGCAG CUGCUCCUA CAGACCCG 1718 UACAAGCA CUGAUGA X GAA ACGGGCUU AAGCCCGUA UGCUUGUA 1723 UUCUUUAC CUGAUGA X GAA AGCAUACG CGUAUGCUU GUAAAGAA 1726 CCAUUCUU CUGAUGA X GAA ACAAGCAU AUGCUUGUA AAGAAUGG 1750 CCCCUGGA CUGAUGA X GAA AUCCUCCA UGGAGGAUU UCCAGGGG 1751 CCCCCUGG CUGAUGA X GAA AAUCCUCC GGAGGAUUU CCAGGGGG 1752 CCCCCCUG CUGAUGA X GAA AAAUCCUC GAGGAUUUC CAGGGGGG 1770 GUGACUUC CUGAUGA X GAA AUCUUGUU AACAAGAUC GAAGUCAC 1776 UUUUUGGU CUGAUGA X GAA ACUUCGAU AUCGAAGUC ACCAAAAA 1790 UCAGGGCA CUGAUGA X GAA AUUGGUUU AAACCAAUA UGCCCUGA 1800 UUUCCUUC CUGAUGA X GAA AUCAGGGC GCCCUGAUU GAAGGAAA 1821 AGCGUACU CUGAUGA X GAA ACAGUUUU AAAACUGUA AGUACGCU 1825 GACCAGCG CUGAUGA X GAA ACUUACAG CUGUAAGUA CGCUGGUC 1833 GCUUGGAU CUGAUGA X GAA ACCAGCGU ACGCUGGUC AUCCAAGC 1836 GCAGCUUG CUGAUGA X GAA AUGACCAG CUGGUCAUC CAAGCUGC 1853 ACAACGCU CUGAUGA X GAA ACACGUUG CAACGUGUC AGCGUUGU 1859 AUUUGUAC CUGAUGA X GAA ACGCUGAC GUCAGCGUU GUACAAAU 1862 CACAUUUG CUGAUGA X GAA ACAACGCU AGCGUUGUA CAAAUGUG 1878 GCUUUGUU CUGAUGA X GAA AUGGCUUC GAAGCCAUC AACAAAGC 1905 AAGGAGAU CUGAUGA X GAA ACCCUCUC GAGAGGGUC AUCUCCUU 1908 UGGAAGGA CUGAUGA X GAA AUGACCCU AGGGUCAUC UCCUUCCA 1910 CAUGGAAG CUGAUGA X GAA AGAUGACC GGUCAUCUC CUUCCAUG 1913 UCACAUGG CUGAUGA X GAA AGGAGAUG CAUCUCCUU CCAUGUGA 1914 AUCACAUG CUGAUGA X GAA AAGGAGAU AUCUCCUUC CAUGUGAU 1923 GGACCCCU CUGAUGA X GAA AUCACAUG CAUGUGAUC AGGGGUCC 1930 AAUUUCAG CUGAUGA X GAA ACCCCUGA UCAGGGGUC CUGAAAUU 1938 UGCACAGU CUGAUGA X GAA AUUUCAGG CCUGAAAUU ACUGUGCA 1939 UUGCACAG CUGAUGA X GAA AAUUUCAG CUGAAAUUA CUGUGCAA 1982 ACAACAGG CUGAUGA X GAA ACACACUC GAGUGUGUC CCUGUUGU 1988 CAGUGCAC CUGAUGA X GAA ACAGGGAC GUCCCUGUU GUGCACUG 2008 CUCAAACG CUGAUGA X GAA AUUUCUGU ACAGAAAUA CGUUUGAG 2012 GGUUCUCA CUGAUGA X GAA ACGUAUUU AAAUACGUU UGAGAACC 2013 AGGUUCUC CUGAUGA X GAA AACGUAUU AAUACGUUU GAGAACCU 2022 UACCACGU CUGAUGA X GAA AGGUUCUC GAGAACCUC ACGUGGUA 2030 CAAGCUUG CUGAUGA X GAA ACCACGUG CACGUGGUA CAAGCUUG 2037 UGUGAGCC CUGAUGA X GAA AGCUUGUA UACAAGCUU GGCUCACA 2042 UUGCCUGU CUGAUGA X GAA AGCCAAGC GCUUGGCUC ACAGGCAA 2054 UGUGGACC CUGAUGA X GAA AUGUUGCC GGCAACAUC GGUCCACA 2058 CCCAUGUG CUGAUGA X GAA ACCGAUGU ACAUCGGUC CACAUGGG 2072 GUGUGAGU CUGAUGA X GAA AUUCGCCC GGGCGAAUC ACUCACAC 2076 ACUGGUGU CUGAUGA X GAA AGUGAUUC GAAUCACUC ACACCAGU 2085 UUCUUGCA CUGAUGA X GAA ACUGGUGU ACACCAGUU UGCAAGAA 2086 GUUCUUGC CUGAUGA X GAA AACUGGUG CACCAGUUU GCAAGAAC 2096 GAGCAUCC CUGAUGA X GAA AGUUCUUG CAAGAACUU GGAUGCUC 2104 UUUCCAAA CUGAUGA X GAA AGCAUCCA UGGAUGCUC UUUGGAAA 2106 AGUUUCCA CUGAUGA X GAA AGAGCAUC GAUGCUCUU UGGAAACU 2107 CAGUUUCC CUGAUGA X GAA AAGAGCAU AUGCUCUUU GGAAACUG 2129 UGUUAGAA CUGAUGA X GAA ACAUGGUG CACCAUGUU UUCUAACA 2130 CUGUUAGA CUGAUGA X GAA AACAUGGU ACCAUGUUU UCUAACAG 2131 GCUGUUAG CUGAUGA X GAA AAACAUGG CCAUGUUUU CUAACAGC 2132 UGCUGUUA CUGAUGA X GAA AAAACAUG CAUGUUUUC UAACAGCA 2134 UGUGCUGU CUGAUGA X GAA AGAAAACA UGUUUUCUA ACAGCACA 2151 ACAAUCAA CUGAUGA X GAA AUGUCAUU AAUGACAUC UUGAUUGU 2153 CCACAAUC CUGAUGA X GAA AGAUGUCA UGACAUCUU GAUUGUGG 2157 AAUGCCAC CUGAUGA X GAA AUCAAGAU AUCUUGAUU GUGGCAUU 2165 CAUUCUGA CUGAUGA X GAA AUGCCACA UGUGGCAUU UCAGAAUG 2166 GCAUUCUG CUGAUGA X GAA AAUGCCAC GUGGCAUUU CAGAAUGC 2167 GGCAUUCU CUGAUGA X GAA AAAUGCCA UGGCAUUUC AGAAUGCC 2177 CCUGCAGA CUGAUGA X GAA AGGCAUUC GAAUGCCUC UCUGCAGG 2179 GUCCUGCA CUGAUGA X GAA AGAGGCAU AUGCCUCUC UGCAGGAC 2198 AGCAAACA CUGAUGA X GAA AGUCGCCU AGGCGACUA UGUUUGCU 2202 GCAGAGCA CUGAUGA X GAA ACAUAGUC GACUAUGUU UGCUCUGC 2203 AGCAGAGC CUGAUGA X GAA AACAUAGU ACUAUGUUU GCUCUGCU 2207 CUUGAGCA CUGAUGA X GAA AGCAAACA UGUUUGCUC UGCUCAAG 2212 CUUAUCUU CUGAUGA X GAA AGCAGAGC GCUCUGCUC AAGAUAAG 2218 GGUCUUCU CUGAUGA X GAA AUCUUGAG CUCAAGAUA AGAAGACC 2239 GACCAGGC CUGAUGA X GAA AUGUCUUU AAAGACAUU GCCUGGUC 2247 AGCUGUUU CUGAUGA X GAA ACCAGGCA UGCCUGGUC AAACAGCU 2256 AGGAUGAU CUGAUGA X GAA AGCUGUUU AAACAGCUC AUCAUCCU 2259 UCUAGGAU CUGAUGA X GAA AUGAGCUG CAGCUCAUC AUCCUAGA 2262 CGCUCUAG CUGAUGA X GAA AUGAUGAG CUCAUCAUC CUAGAGCG 2265 AUGCGCUC CUGAUGA X GAA AGGAUGAU AUCAUCCUA GAGCGCAU 2286 UUUCCGGU CUGAUGA X GAA AUCAUGGG CCCAUGAUC ACCGGAAA 2296 AUUCUCCA CUGAUGA X GAA AUUUCCGG CCGGAAAUC UGGAGAAU 2305 UGUUGUCU CUGAUGA X GAA AUUCUCCA UGGAGAAUC AGACAACA 2319 GUCUCGCC CUGAUGA X GAA AUGGUUGU ACAACCAUU GGCGAGAC 2331 GUCACUUC CUGAUGA X GAA AUGGUCUC GAGACCAUU GAAGUGAC 2341 UGCUGGGC CUGAUGA X GAA AGUCACUU AAGUGACUU GCCCAGCA 2351 GAUUUCCA CUGAUGA X GAA AUGCUGGG CCCAGCAUC UGGAAAUC 2359 UGGGGUAG CUGAUGA X GAA AUUUCCAG CUGGAAAUC CUACCCCA 2362 GUGUGGGG CUGAUGA X GAA AGGAUUUC GAAAUCCUA CCCCACAC 2373 AACCAUGU CUGAUGA X GAA AUGUGUGG CCACACAUU ACAUGGUU 2374 GAACCAUG CUGAUGA X GAA AAUGUGUG CACACAUUA CAUGGUUC 2381 UGUCUUUG CUGAUGA X GAA ACCAUGUA UACAUGGUU CAAAGACA 2382 UUGUCUUU CUGAUGA X GAA AACCAUGU ACAUGGUUC AAAGACAA 2403 GAAUCUUC CUGAUGA X GAA ACCAGGGU ACCCUGGUA GAAGAUUC 2410 AAUGCCUG CUGAUGA X GAA AUCUUCUA UAGAAGAUU CAGGCAUU 2411 CAAUGCCU CUGAUGA X GAA AAUCUUCU AGAAGAUUC AGGCAUUG 2418 CUCAGUAC CUGAUGA X GAA AUGCCUGA UCAGGCAUU GUACUGAG 2421 UCUCUCAG CUGAUGA X GAA ACAAUGCC GGCAUUGUA CUGAGAGA 2449 CCUGCGGA CUGAUGA X GAA AGUCAGGU ACCUGACUA UCCGCAGG 2451 ACCCUGCG CUGAUGA X GAA AUAGUCAG CUGACUAUC CGCAGGGU 2481 CAGGUGUA CUGAUGA X GAA AGGCCUCC GGAGGCCUC UACACCUG 2483 GGCAGGUG CUGAUGA X GAA AGAGGCCU AGGCCUCUA CACCUGCC 2505 CAGCCAAG CUGAUGA X GAA ACAUUGCA UGCAAUGUC CUUGGCUG 2508 GCACAGCC CUGAUGA X GAA AGGACAUU AAUGUCCUU GGCUGUGC 2532 AUUAUGAA CUGAUGA X GAA AGCGUCUC GAGACGCUC UUCAUAAU 2534 CUAUUAUG CUGAUGA X GAA AGAGCGUC GACGCUCUU CAUAAUAG 2535 UCUAUUAU CUGAUGA X GAA AAGAGCGU ACGCUCUUC AUAAUAGA 2538 CCUUCUAU CUGAUGA X GAA AUGAAGAG CUCUUCAUA AUAGAAGG 2541 GCACCUUC CUGAUGA X GAA AUUAUGAA UUCAUAAUA GAAGGUGC 2567 UGACUUCC CUGAUGA X GAA AGUUGGUC GACCAACUU GGAAGUCA 2574 AGGAUAAU CUGAUGA X GAA ACUUCCAA UUGGAAGUC AUUAUCCU 2577 ACGAGGAU CUGAUGA X GAA AUGACUUC GAAGUCAUU AUCCUCGU 2578 GACGAGGA CUGAUGA X GAA AAUGACUU AAGUCAUUA UCCUCGUC 2580 CCGACGAG CUGAUGA X GAA AUAAUGAC GUCAUUAUC CUCGUCGG 2583 GUGCCGAC CUGAUGA X GAA AGGAUAAU AUUAUCCUC GUCGGCAC 2586 GCAGUGCC CUGAUGA X GAA ACGAGGAU AUCCUCGUC GGCACUGC 2797 GCGGCCAA CUGAUGA X GAA AGGUUUUC GAAAACCUC UUGGCCGC 2799 CCGCGGCC CUGAUGA X GAA AGAGGUUU AAACCUCUU GGCCGCGG 2813 CUUGGCCG CUGAUGA X GAA AGGCACCG CGGUGCCUU CGGCCAAG 2814 ACUUGGCC CUGAUGA X GAA AAGGCACC GGUGCCUUC GGCCAAGU 2826 UCUGCCUC CUGAUGA X GAA AUCACUUG CAAGUGAUU GAGGCAGA 2839 AAUUCCAA CUGAUGA X GAA AGCGUCUG CAGACGCUU UUGGAAUU 2840 CAAUUCCA CUGAUGA X GAA AAGCGUCU AGACGCUUU UGGAAUUG 2841 UCAAUUCC CUGAUGA X GAA AAAGCGUC GACGCUUUU GGAAUUGA 2847 GUCUUGUC CUGAUGA X GAA AUUCCAAA UUUGGAAUU GACAAGAC 2863 UGUUUUGC CUGAUGA X GAA AGUCGCUG CAGCGACUU GCAAAACA 2874 UUGACGGC CUGAUGA X GAA ACUGUUUU AAAACAGUA GCCGUCAA 2880 AACAUCUU CUGAUGA X GAA ACGGCUAC GUAGCCGUC AAGAUGUU 2888 CUUCUUUC CUGAUGA X GAA ACAUCUUG CAAGAUGUU GAAAGAAG 2917 GAGGGCUC CUGAUGA X GAA AUGCUCGC GCGAGCAUC GAGCCCUC 2925 UCAGACAU CUGAUGA X GAA AGGGCUCG CGAGCCCUC AUGUCUGA 2930 UGAGUUCA CUGAUGA X GAA ACAUGAGG CCUCAUGUC UGAACUCA 2937 AGGAUCUU CUGAUGA X GAA AGUUCAGA UCUGAACUC AAGAUCCU 29 3 UGGAUGAG CUGAUGA X GAA AUCUUGAG CUCAAGAUC CUCAUCCA 2946 AUGUGGAU CUGAUGA X GAA AGGAUCUU AAGAUCCUC AUCCACAU 2949 CCAAUGUG CUGAUGA X GAA AUGAGGAU AUCCUCAUC CACAUUGG 2955 UGGUGACC CUGAUGA X GAA AUGUGGAU AUCCACAUU GGUCACCA 2959 GAGAUGGU CUGAUGA X GAA ACCAAUGU ACAUUGGUC ACCAUCUC 2965 CACAUUGA CUGAUGA X GAA AUGGUGAC GUCACCAUC UCAAUGUG 2967 ACCACAUU CUGAUGA X GAA AGAUGGUG CACCAUCUC AAUGUGGU 2982 GCGCCUAG CUGAUGA X GAA AGGUUCAC GUGAACCUC CUAGGCGC 2985 CAGGCGCC CUGAUGA X GAA AGGAGGUU AACCUCCUA GGCGCCUG 3013 CACCAUGA CUGAUGA X GAA AGGCCCUC GAGGGCCUC UCAUGGUG 3015 AUCACCAU CUGAUGA X GAA AGAGGCCC GGGCCUCUC AUGGUGAU 3024 AAUUCCAC CUGAUGA X GAA AUCACCAU AUGGUGAUU GUGGAAUU 3032 ACUUGCAG CUGAUGA X GAA AUUCCACA UGUGGAAUU CUGCAAGU GAA AAUUCCAC GUGGAAUUC UGCAAGUU GAA ACUUGCAG CUGCAAGUU UGGAAACC GAA AACUUGCA UGCAAGUUU GGAAACCU GAA AGGUUUCC GGAAACCUA UCAACUUA GAA AUAGGUUU AAACCUAUC AACUUACU GAA AGUUGAUA UAUCAACUU ACUUACGG GAA AAGUUGAU AUCAACUUA CUUACGGG GAA AGUAAGUU AACUUACUU ACGGGGCA GAA AAGUAAGU ACUUACUUA CGGGGCAA GAA AUUCAUUU AAAUGAAUU UGUUCCCU GAA AAUUCAUU AAUGAAUUU GUUCCCUA GAA ACAAAUUC GAAUUUGUU CCCUAUAA GAA AACAAAUU AAUUUGUUC CCUAUAAG GAA AGGGAACA UGUUCCCUA UAAGAGCA GAA AUAGGGAA UUCCCUAUA AGAGCAAA GAA AGCGUGCC GGCACGCUU CCGCCAGG GAA AAGCGUGC GCACGCUUC CGCCAGGG GAA AGUCCUUG CAAGGACUA CGUUGGGG GAA ACGUAGUC GACUACGUU GGGGAGCU GAA AGCUCCCC GGGGAGCUC UCCGUGGA GAA AGAGCUCC GGAGCUCUC CGUGGAUC GAA AUCCACGG CCGUGGAUC UGAAAAGA GAA AGCGUCUU AAGACGCUU GGACAGCA GAA AUGCUGUC GACAGCAUC ACCAGCAG GAA AGCUCUGG CCAGAGCUC UGCCAGCU GAA AGCUGGCA UGCCAGCUC AGGCUUUG GAA AGCCUGAG CUCAGGCUU UGUUGAGG GAA AAGCCUGA UCAGGCUUU GUUGAGGA GAA ACAAAGCC GGCUUUGUU GAGGAGAA GAA AUUUCUCC GGAGAAAUC GCUCAGUG 3228 ACAUCACU CUGAUGA X GAA AGCGAUUU AAAUCGCUC AGUGAUGU 3237 UCUUCCUC CUGAUGA X GAA ACAUCACU AGUGAUGUA GAGGAAGA 3253 UUCUUCAG CUGAUGA X GAA AGCUUCUU AAGAAGCUU CUGAAGAA 3254 GUUCUUCA CUGAUGA X GAA AAGCUUCU AGAAGCUUC UGAAGAAC 3266 AGUCCUUG CUGAUGA X GAA ACAGUUCU AGAACUGUA CAAGGACU 3275 AGGUCAGG CUGAUGA X GAA AGUCCUUG CAAGGACUU CCUGACCU 3276 AAGGUCAG CUGAUGA X GAA AAGUCCUU AAGGACUUC CUGACCUU 3284 GAUGCUCC CUGAUGA X GAA AGGUCAGG CCUGACCUU GGAGCAUC 3292 ACAGAUGA CUGAUGA X GAA AUGCUCCA UGGAGCAUC UCAUCUGU 3294 UAACAGAU CUGAUGA X GAA AGAUGCUC GAGCAUCUC AUCUGUUA 3297 CUGUAACA CUGAUGA X GAA AUGAGAUG CAUCUCAUC UGUUACAG 3301 GAAGCUGU CUGAUGA X GAA ACAGAUGA UCAUCUGUU ACAGCUUC 3302 GGAAGCUG CUGAUGA X GAA AACAGAUG CAUCUGUUA CAGCUUCC 3308 CCACUUGG CUGAUGA X GAA AGCUGUAA UUACAGCUU CCAAGUGG 3309 GCCACUUG CUGAUGA X GAA AAGCUGUA UACAGCUUC CAAGUGGC 3319 CAUGCCCU CUGAUGA X GAA AGCCACUU AAGUGGCUA AGGGCAUG 3332 AUGCCAAG CUGAUGA X GAA ACUCCAUG CAUGGAGUU CUUGGCAU 3333 GAUGCCAA CUGAUGA X GAA AACUCCAU AUGGAGUUC UUGGCAUC 3335 UUGAUGCC CUGAUGA X GAA AGAACUCC GGAGUUCUU GGCAUCAA 3341 ACUUCCUU CUGAUGA X GAA AUGCCAAG CUUGGCAUC AAGGAAGU 3352 CCUGUGGA CUGAUGA X GAA ACACUUCC GGAAGUGUA UCCACAGG 3354 UCCCUGUG CUGAUGA X GAA AUACACUU AAGUGUAUC CACAGGGA 3381 GAUAGGAG CUGAUGA X GAA AUGUUUCG CGAAACAUU CUCCUAUC 3382 CGAUAGGA CUGAUGA X GAA AAUGUUUC GAAACAUUC UCCUAUCG 3384 UCCGAUAG CUGAUGA X GAA AGAAUGUU AACAUUCUC CUAUCGGA 3387 UUCUCCGA CUGAUGA X GAA AGGAGAAU AUUCUCCUA UCGGAGAA 3389 UCUUCUCC CUGAUGA X GAA AUAGGAGA UCUCCUAUC GGAGAAGA 3405 CAGAUCUU CUGAUGA X GAA ACCACAUU AAUGUGGUU AAGAUCUG 3406 ACAGAUCU CUGAUGA X GAA AACCACAU AUGUGGUUA AGAUCUGU 3411 AAGUCACA CUGAUGA X GAA AUCUUAAC GUUAAGAUC UGUGACUU 3419 CCAAGCCG CUGAUGA X GAA AGUCACAG CUGUGACUU CGGCUUGG 3420 GCCAAGCC CUGAUGA X GAA AAGUCACA UGUGACUUC GGCUUGGC 3425 CCCGGGCC CUGAUGA X GAA AGCCGAAG CUUCGGCUU GGCCCGGG 3438 UCUUUAUA CUGAUGA X GAA AUGUCCCG CGGGACAUU UAUAAAGA 3439 GUCUUUAU CUGAUGA X GAA AAUGUCCC GGGACAUUU AUAAAGAC 3440 GGUCUUUA CUGAUGA X GAA AAAUGUCC GGACAUUUA UAAAGACC 3442 CGGGUCUU CUGAUGA X GAA AUAAAUGU ACAUUUAUA AAGACCCG 3454 UCUGACAU CUGAUGA X GAA AUCCGGGU ACCCGGAUU AUGUCAGA 3455 UUCUGACA CUGAUGA X GAA AAUCCGGG CCCGGAUUA UGUCAGAA 3459 CCUUUUCU CUGAUGA X GAA ACAUAAUC GAUUAUGUC AGAAAAGG 3480 UUCAAAGG CUGAUGA X GAA AGUCGGGC GCCCGACUC CCUUUGAA 3484 CCACUUCA CUGAUGA X GAA AGGGAGUC GACUCCCUU UGAAGUGG 3485 UCCACUUC CUGAUGA X GAA AAGGGAGU ACUCCCUUU GAAGUGGA 3510 CUGUCAAA CUGAUGA X GAA AUGGUUUC GAAACCAUU UUUGACAG 3511 UCUGUCAA CUGAUGA X GAA AAUGGUUU AAACCAUUU UUGACAGA 3512 CUCUGUCA CUGAUGA X GAA AAAUGGUU AACCAUUUU UGACAGAG 3513 ACUCUGUC CUGAUGA X GAA AAAAUGGU ACCAUUUUU GACAGAGU 3522 AUUGUGUA CUGAUGA X GAA ACUCUGUC GACAGAGUA UACACAAU 3524 GAAUUGUG CUGAUGA X GAA AUACUCUG CAGAGUAUA CACAAUUC 3531 UCGCUCUG CUGAUGA X GAA AUUGUGUA UACACAAUU CAGAGCGA 3532 AUCGCUCU CUGAUGA X GAA AAUUGUGU ACACAAUUC AGAGCGAU 3548 CACCGAAA CUGAUGA X GAA ACCACACA UGUGUGGUC UUUCGGUG 3550 CACACCGA CUGAUGA X GAA AGACCACA UGUGGUCUU UCGGUGUG 3551 ACACACCG CUGAUGA X GAA AAGACCAC GUGGUCUUU CGGUGUGU 3552 AACACACC CUGAUGA X GAA AAAGACCA UGGUCUUUC GGUGUGUU 3560 CCCAGAGC CUGAUGA X GAA ACACACCG CGGUGUGUU GCUCUGGG 3564 AUUUCCCA CUGAUGA X GAA AGCAACAC GUGUUGCUC UGGGAAAU 3573 AAGGAAAA CUGAUGA X GAA AUUUCCCA UGGGAAAUA UUUUCCUU 3575 CUAAGGAA CUGAUGA X GAA AUAUUUCC GGAAAUAUU UUCCUUAG 3576 CCUAAGGA CUGAUGA X GAA AAUAUUUC GAAAUAUUU UCCUUAGG 3577 ACCUAAGG CUGAUGA X GAA AAAUAUUU AAAUAUUUU CCUUAGGU 3578 CACCUAAG CUGAUGA X GAA AAAAUAUU AAUAUUUUC CUUAGGUG 3581 AGGCACCU CUGAUGA X GAA AGGAAAAU AUUUUCCUU AGGUGCCU 3582 GAGGCACC CUGAUGA X GAA AAGGAAAA UUUUCCUUA GGUGCCUC 3590 GGUAUGGG CUGAUGA X GAA AGGCACCU AGGUGCCUC CCCAUACC 3596 CCCCAGGG CUGAUGA X GAA AUGGGGAG CUCCCCAUA CCCUGGGG 3606 UCAAUCUU CUGAUGA X GAA ACCCCAGG CCUGGGGUC AAGAUUGA 3612 UCUUCAUC CUGAUGA X GAA AUCUUGAC GUCAAGAUU GAUGAAGA 3623 UCCUACAA CUGAUGA X GAA AUUCUUCA UGAAGAAUU UUGUAGGA 3624 CUCCUACA CUGAUGA X GAA AAUUCUUC GAAGAAUUU UGUAGGAG 3625 UCUCCUAC CUGAUGA X GAA AAAUUCUU AAGAAUUUU GUAGGAGA 3628 CAAUCUCC CUGAUGA X GAA ACAAAAUU AAUUUUGUA GGAGAUUG 3635 CUUCUUUC CUGAUGA X GAA AUCUCCUA UAGGAGAUU GAAAGAAG 3649 CCGCAUUC CUGAUGA X GAA AGUUCCUU AAGGAACUA GAAUGCGG 3661 GUAGUCAG CUGAUGA X GAA AGCCCGCA UGCGGGCUC CUGACUAC 3668 GGGUAGUG CUGAUGA X GAA AGUCAGGA UCCUGACUA CACUACCC 3673 UUCUGGGG CUGAUGA X GAA AGUGUAGU ACUACACUA CCCCAGAA 3686 UGGUCUGG CUGAUGA X GAA ACAUUUCU AGAAAUGUA CCAGACCA 3734 CUGAAAAC CUGAUGA X GAA AGGGUCUC GAGACCCUC GUUUUCAG 3737 ACUCUGAA CUGAUGA X GAA ACGAGGGU ACCCUCGUU UUCAGAGU 3738 AACUCUGA CUGAUGA X GAA AACGAGGG CCCUCGUUU UCAGAGUU 3739 CAACUCUG CUGAUGA X GAA AAACGAGG CCUCGUUUU CAGAGUUG 3740 CCAACUCU CUGAUGA X GAA AAAACGAG CUCGUUUUC AGAGUUGG 3746 GCUCCACC CUGAUGA X GAA ACUCUGAA UUCAGAGUU GGUGGAGC 3757 GUUUCCCA CUGAUGA X GAA AUGCUCCA UGGAGCAUU UGGGAAAC 3758 GGUUUCCC CUGAUGA X GAA AAUGCUCC GGAGCAUUU GGGAAACC 3768 GCUUGCAG CUGAUGA X GAA AGGUUUCC GGAAACCUC CUGCAAGC 3803 GAACAAUA CUGAUGA X GAA AGUCUUUG CAAAGACUA UAUUGUUC 3805 AAGAACAA CUGAUGA X GAA AUAGUCUU AAGACUAUA UUGUUCUU 3807 GGAAGAAC CUGAUGA X GAA AUAUAGUC GACUAUAUU GUUCUUCC 3810 AUUGGAAG CUGAUGA X GAA ACAAUAUA UAUAUUGUU CUUCCAAU 3811 CAUUGGAA CUGAUGA X GAA AACAAUAU AUAUUGUUC UUCCAAUG 3813 GACAUUGG CUGAUGA X GAA AGAACAAU AUUGUUCUU CCAAUGUC 3814 UGACAUUG CUGAUGA X GAA AAGAACAA UUGUUCUUC CAAUGUCA 3821 GUGUCUCU CUGAUGA X GAA ACAUUGGA UCCAAUGUC AGAGACAC 3847 GAGUCCAG CUGAUGA X GAA AUCCUCUU AAGAGGAUU CUGGACUC 3848 AGAGUCCA CUGAUGA X GAA AAUCCUCU AGAGGAUUC UGGACUCU 3855 GGCAGGGA CUGAUGA X GAA AGUCCAGA UCUGGACUC UCCCUGCC 3857 UAGGCAGG CUGAUGA X GAA AGAGUCCA UGGACUCUC CCUGCCUA 3865 AGGUGAGG CUGAUGA X GAA AGGCAGGG CCCUGCCUA CCUCACCU 3869 AAACAGGU CUGAUGA X GAA AGGUAGGC GCCUACCUC ACCUGUUU 3876 AUACAGGA CUGAUGA X GAA ACAGGUGA UCACCUGUU UCCUGUAU 3877 CAUACAGG CUGAUGA X GAA AACAGGUG CACCUGUUU CCUGUAUG 3878 CCAUACAG CUGAUGA X GAA AAACAGGU ACCUGUUUC CUGUAUGG 3883 UUCCUCCA CUGAUGA X GAA ACAGGAAA UTJUCCUGUA UGGAGGAA 3914 CAUAAUGG CUGAUGA X GAA AUUUGGGG CCCCAAAUU CCAUUAUG 3915 UCAUAAUG CUGAUGA X GAA AAUUUGGG CCCAAAUUC CAUUAUGA 3919 GUUGUCAU CUGAUGA X GAA AUGGAAUU AAUUCCAUU AUGACAAC 3920 UGUUGUCA CUGAUGA X GAA AAUGGAAU AUUCCAUUA UGACAACA 3939 UAAUGACU CUGAUGA X GAA AUUCCUGC GCAGGAAUC AGUCAUUA 3943 GAGAUAAU CUGAUGA X GAA ACUGAUUC GAAUCAGUC AUUAUCUC 3946 CUGGAGAU CUGAUGA X GAA AUGACUGA UCAGUCAUU AUCUCCAG 3947 UCUGGAGA CUGAUGA X GAA AAUGACUG CAGUCAUUA UCUCCAGA 3949 GUUCUGGA CUGAUGA X GAA AUAAUGAC GUCAUUAUC UCCAGAAC 3951 CUGUUCUG CUGAUGA X GAA AGAUAAUG CAUUAUCUC CAGAACAG 3961 CUUUCGCU CUGAUGA X GAA ACUGUUCU AGAACAGUA AGCGAAAG 3987 AAUGUUUU CUGAUGA X GAA ACACUCAC GUGAGUGUA AAAACAUU 3995 UAUCUUCA CUGAUGA X GAA AUGUUUUU AAAAACAUU UGAAGAUA 3996 AUAUCUUC CUGAUGA X GAA AAUGUUUU AAAACAUUU GAAGAUAU 4003 CAAUGGGA CUGAUGA X GAA AUCUUCAA UUGAAGAUA UCCCAUUG 4005 UCCAAUGG CUGAUGA X GAA AUAUCUUC GAAGAUAUC CCAUUGGA 4010 GUUCCUCC CUGAUGA X GAA AUGGGAUA UAUCCCAUU GGAGGAAC 4026 AUCACUUU CUGAUGA X GAA ACUUCUGG CCAGAAGUA AAAGUGAU 4035 UCAUCUGG CUGAUGA X GAA AUCACUUU AAAGUGAUC CCAGAUGA 4068 GAUGCAAG CUGAUGA X GAA ACCAUCCC GGGAUGGUC CUUGCAUC 4071 UCUGAUGC CUGAUGA X GAA AGGACCAU AUGGUCCUU GCAUCAGA 4076 GCUCUUCU CUGAUGA X GAA AUGCAAGG CCUUGCAUC AGAAGAGC 4093 GUCUUCCA CUGAUGA X GAA AGUUUUCA UGAAAACUC UGGAAGAC 4112 AUGGAGAU CUGAUGA X GAA AUUUGUUC GAACAAAUU AUCUCCAU 4113 GAUGGAGA CUGAUGA X GAA AAUUUGUU AACAAAUUA UCUCCAUC 4115 AAGAUGGA CUGAUGA X GAA AUAAUUUG CAAAUUAUC UCCAUCUU 4117 AAAAGAUG CUGAUGA X GAA AGAUAAUU AAUUAUCUC CAUCUUUU 4121 CACCAAAA CUGAUGA X GAA AUGGAGAU AUCUCCAUC UUUUGGUG 4123 UCCACCAA CUGAUGA X GAA AGAUGGAG CUCCAUCUU UUGGUGGA 124 UUCCACCA CUGAUGA X GAA AAGAUGGA UCCAUCUUU UGGUGGAA 4125 AUUCCACC CUGAUGA X GAA AAAGAUGG CCAUCUUUU GGUGGAAU 4144 CCUGCUUU CUGAUGA X GAA ACUGGGCA UGCCCAGUA AAAGCAGG 4157 AGGCCACA CUGAUGA X GAA ACUCCCUG CAGGGAGUC UGUGGCCU 4166 AGCCUUCC CUGAUGA X GAA AGGCCACA UGUGGCCUC GGAAGGCU 4175 UCUGGUUG CUGAUGA X GAA AGCCUUCC GGAAGGCUC CAACCAGA 4193 CAGACUGG CUGAUGA X GAA AGCCACUG CAGUGGCUA CCAGUCUG 4199 GAUACCCA CUGAUGA X GAA ACUGGUAG CUACCAGUC UGGGUAUC 4205 CUGAGUGA CUGAUGA X GAA ACCCAGAC GUCUGGGUA UCACUCAG 4207 AUCUGAGU CUGAUGA X GAA AUACCCAG CUGGGUAUC ACUCAGAU 4211 UGUCAUCU CUGAUGA X GAA AGUGAUAC GUAUCACUC AGAUGACA 4235 CGCUGGAG CUGAUGA X GAA ACACGGUG CACCGUGUA CUCCAGCG 4238 CGUCGCUG CUGAUGA X GAA AGUACACG CGUGUACUC CAGCGACG 4257 AUCUUUAA CUGAUGA X GAA AGUCCUGC GCAGGACUU UUAAAGAU 4258 CAUCUUUA CUGAUGA X GAA AAGUCCUG CAGGACUUU UAAAGAUG 4259 CCAUCUUU CUGAUGA X GAA AAAGUCCU AGGACUUUU AAAGAUGG 4439 AAAAAUGA CUGAUGA X GAA AAUCAAAU AUUUGAUUU UCAUUUUU 4440 CAAAAAUG CUGAUGA X GAA AAAUCAAA UUUGAUUUU CAUUUUUG 4441 CCAAAAAU CUGAUGA X GAA AAAAUCAA UUGAUUUUC AUUUUUGG 4444 CCUCCAAA CUGAUGA X GAA AUGAAAAU AUUUUCAUU UUUGGAGG 4445 UCCUCCAA CUGAUGA X GAA AAUGAAAA UUUUCAUUU UUGGAGGA 4446 CUCCUCCA CUGAUGA X GAA AAAUGAAA UUUCAUUUU UGGAGGAG 4447 CCUCCUCC CUGAUGA X GAA AAAAUGAA UUCAUUUUU GGAGGAGG 4461 UGCAGUCU CUGAUGA X GAA AGGUCCCU AGGGACCUC AGACUGCA 4477 CUGAGGAC CUGAUGA X GAA AGCUCCUU AAGGAGCUU GUCCUCAG 4480 GCCCUGAG CUGAUGA X GAA ACAAGCUC GAGCUUGUC CUCAGGGC 4483 AAUGCCCU CUGAUGA X GAA AGGACAAG CUUGUCCUC AGGGCAUU 4491 UCUCUGGA CUGAUGA X GAA AUGCCCUG CAGGGCAUU UCCAGAGA 4492 UUCUCUGG CUGAUGA X GAA AAUGCCCU AGGGCAUUU CCAGAGAA 4493 CUUCUCUG CUGAUGA X GAA AAAUGCCC GGGCAUUUC CAGAGAAG 4525 GUAGAGUC CUGAUGA X GAA ACACAUUC GAAUGUGUU GACUCUAC 4530 AGAGAGUA CUGAUGA X GAA AGUCAACA UGUUGACUC UACUCUCU 4532 AAAGAGAG CUGAUGA X GAA AGAGUCAA UUGACUCUA CUCUCUUU 4535 GGAAAAGA CUGAUGA X GAA AGUAGAGU ACUCUACUC UCUUUUCC 4537 AUGGAAAA CUGAUGA X GAA AGAGUAGA UCUACUCUC UUUUCCAU 4539 GAAUGGAA CUGAUGA X GAA AGAGAGUA UACUCUCUU UUCCAUUC 4540 UGAAUGGA CUGAUGA X GAA AAGAGAGU ACUCUCUUU UCCAUUCA 4541 AUGAAUGG CUGAUGA X GAA AAAGAGAG CUCUCUUUU CCAUUCAU 4542 AAUGAAUG CUGAUGA X GAA AAAAGAGA UCUCUUUUC CAUUCAUU 4546 UUUAAAUG CUGAUGA X GAA AUGGAAAA UUUUCCAUU CAUUUAAA 4547 UUUUAAAU CUGAUGA X GAA AAUGGAAA UUUCCAUUC AUUUAAAA 4550 GACUUUUA CUGAUGA X GAA AUGAAUGG CCAUUCAUU UAAAAGUC 4551 GGACUUUU CUGAUGA X GAA AAUGAAUG CAUUCAUUU AAAAGUCC 4552 AGGACUUU CUGAUGA X GAA AAAUGAAU AUUCAUUUA AAAGUCCU 4558 UUAUAUAG CUGAUGA X GAA ACUUUUAA UUAAAAGUC CUAUAUAA 4561 ACAUUAUA CUGAUGA X GAA AGGACUUU AAAGUCCUA UAUAAUGU 4563 GCACAUUA CUGAUGA X GAA AUAGGACU AGUCCUAUA UAAUGUGC 4565 GGGCACAU CUGAUGA X GAA AUAUAGGA UCCUAUAUA AUGUGCCC 4583 GGUAGUGA CUGAUGA X GAA ACCACAGC GCUGUGGUC UCACUACC 4585 CUGGUAGU CUGAUGA X GAA AGACCACA UGUGGUCUC ACUACCAG 4589 UUAACUGG CUGAUGA X GAA AGUGAGAC GUCUCACUA CCAGUUAA 4595 UUUGCUUU CUGAUGA X GAA ACUGGUAG CUACCAGUU AAAGCAAA 4596 UUUUGCUU CUGAUGA X GAA AACUGGUA UACCAGUUA AAGCAAAA 4609 GUGUUUGA CUGAUGA X GAA AGUCUUUU AAAAGACUU UCAAACAC 4610 CGUGUUUG CUGAUGA X GAA AAGUCUUU AAAGACUUU CAAACACG 4611 ACGUGUUU CUGAUGA X GAA AAAGUCUU AAGACUUUC AAACACGU 4625 GGAGGACA CUGAUGA X GAA AGUCCACG CGUGGACUC UGUCCUCC 4629 UCUUGGAG CUGAUGA X GAA ACAGAGUC GACUCUGUC CUCCAAGA 4632 ACUUCUUG CUGAUGA X GAA AGGACAGA UCUGUCCUC CAAGAAGU 4654 GUUUCACA CUGAUGA X GAA AGGUGCCG CGGCACCUC UGUGAAAC 4668 GCCCAUUC CUGAUGA X GAA AUCCAGUU AACUGGAUC GAAUGGGC 4683 AACACACA CUGAUGA X GAA AGCAUUGC GCAAUGCUU UGUGUGUU 4684 CAACACAC CUGAUGA X GAA AAGCAUUG CAAUGCUUU GUGUGUUG 4691 CCAUCCUC CUGAUGA X GAA ACACACAA UUGUGUGUU GAGGAUGG 4709 GGCCCUGG CUGAUGA X GAA ACAUCUCA UGAGAUGUC CCAGGGCC 4722 GGUAGACA CUGAUGA X GAA ACUCGGCC GGCCGAGUC UGUCUACC 726 CCAAGGUA CUGAUGA X GAA ACAGACUC GAGUCUGUC UACCUUGG 4728 CUCCAAGG CUGAUGA X GAA AGACAGAC GUCUGUCUA CCUUGGAG 4732 AAGCCUCC CUGAUGA X GAA AGGUAGAC GUCUACCUU GGAGGCUU 4740 CCUCCACA CUGAUGA X GAA AGCCUCCA UGGAGGCUU UGUGGAGG 4741 UCCUCCAC CUGAUGA X GAA AAGCCUCC GGAGGCUUU GUGGAGGA 4758 UUGGCUCA CUGAUGA X GAA AGCCCGCA UGCGGGCUA UGAGCCAA 4771 CCACACUU CUGAUGA X GAA ACACUUGG CCAAGUGUU AAGUGUGG 772 CCCACACU CUGAUGA X GAA AACACUUG CAAGUGUUA AGUGUGGG 4811 CUCCGAGC CUGAUGA X GAA ACUUGCGC GCGCAAGUC GCUCGGAG 4815 CGCUCUCC CUGAUGA X GAA AGCGACUU AAGUCGCUC GGAGAGCG 4826 CAGGCUCC CUGAUGA X GAA ACCGCUCU AGAGCGGUU GGAGCCUG 4844 GCCAGCAC CUGAUGA X GAA AUGCAUCU AGAUGCAUU GUGCUGGC 4854 CUCCACCA CUGAUGA X GAA AGCCAGCA UGCUGGCUC UGGUGGAG 4870 CAGGCCAC CUGAUGA X GAA AGCCCACC GGUGGGCUU GUGGCCUG 4880 CGUUUCCU CUGAUGA X GAA ACAGGCCA UGGCCUGUC AGGAAACG 4908 CAAAACCA CUGAUGA X GAA ACCCUGCC GGCAGGGUU UGGUUUUG 4909 CCAAAACC CUGAUGA X GAA AACCCUGC GCAGGGUUU GGUUUUGG 4913 CCUUCCAA CUGAUGA X GAA ACCAAACC GGUUUGGUU UUGGAAGG 4914 ACCUUCCA CUGAUGA X GAA AACCAAAC GUUUGGUUU UGGAAGGU 4915 AACCUUCC CUGAUGA X GAA AAACCAAA UUUGGUUUU GGAAGGUU 4923 AGCACGCA CUGAUGA X GAA ACCUUCCA UGGAAGGUU UGCGUGCU 4924 GAGCACGC CUGAUGA X GAA AACCUUCC GGAAGGUUU GCGUGCUC 4932 ACUGUGAA CUGAUGA X GAA AGCACGCA UGCGUGCUC UUCACAGU 4934 CGACUGUG CUGAUGA X GAA AGAGCACG CGUGCUCUU CACAGUCG 4935 CCGACUGU CUGAUGA X GAA AAGAGCAC GUGCUCUUC ACAGUCGG 4941 UGUAACCC CUGAUGA X GAA ACUGUGAA UUCACAGUC GGGUUACA 4946 UCGCCUGU CUGAUGA X GAA ACCCGACU AGUCGGGUU ACAGGCGA 4947 CUCGCCUG CUGAUGA X GAA AACCCGAC GUCGGGUUA CAGGCGAG 4957 CCACAGGG CUGAUGA X GAA ACUCGCCU AGGCGAGUU CCCUGUGG 4958 GCCACAGG CUGAUGA X GAA AACUCGCC GGCGAGUUC CCUGUGGC 4969 GAGUAGGA CUGAUGA X GAA ACGCCACA UGUGGCGUU UCCUACUC 4970 GGAGUAGG CUGAUGA X GAA AACGCCAC GUGGCGUUU CCUACUCC 4971 AGGAGUAG CUGAUGA X GAA AAACGCCA UGGCGUUUC CUACUCCU 4974 AUUAGGAG CUGAUGA X GAA AGGAAACG CGUUUCCUA CUCCUAAU 4977 CUCAUUAG CUGAUGA X GAA AGUAGGAA UUCCUACUC CUAAUGAG 4980 ACUCUCAU CUGAUGA X GAA AGGAGUAG CUACUCCUA AUGAGAGU 4989 CCGGAAGG CUGAUGA X GAA ACUCUCAU AUGAGAGUU CCUUCCGG 4990 UCCGGAAG CUGAUGA X GAA AACUCUCA UGAGAGUUC CUUCCGGA 4993 GAGUCCGG CUGAUGA X GAA AGGAACUC GAGUUCCUU CCGGACUC 4994 AGAGUCCG CUGAUGA X GAA AAGGAACU AGUUCCUUC CGGACUCU 5001 ACACGUAA CUGAUGA X GAA AGUCCGGA UCCGGACUC UUACGUGU 5003 AGACACGU CUGAUGA X GAA AGAGUCCG CGGACUCUU ACGUGUCU 5004 GAGACACG CUGAUGA X GAA AAGAGUCC GGACUCUUA CGUGUCUC 5010 GGCCAGGA CUGAUGA X GAA ACACGUAA UUACGUGUC UCCUGGCC 5012 CAGGCCAG CUGAUGA X GAA AGACACGU ACGUGUCUC CUGGCCUG 5046 GAAGGAGC CUGAUGA X GAA AGCUGCAU AUGCAGCUU GCUCCUUC 5050 UGAGGAAG CUGAUGA X GAA AGCAAGCU AGCUUGCUC CUUCCUCA 5053 AGAUGAGG CUGAUGA X GAA AGGAGCAA UUGCUCCUU CCUCAUCU 5054 GAGAUGAG CUGAUGA X GAA AAGGAGCA UGCUCCUUC CUCAUCUC 5057 UGAGAGAU CUGAUGA X GAA AGGAAGGA UCCUUCCUC AUCUCUCA 5060 GCCUGAGA CUGAUGA X GAA AUGAGGAA UUCCUCAUC UCUCAGGC 5062 CAGCCUGA CUGAUGA X GAA AGAUGAGG CCUCAUCUC UCAGGCUG 5064 CACAGCCU CUGAUGA X GAA AGAGAUGA UCAUCUCUC AGGCUGUG 5076 UCUGAAUU CUGAUGA X GAA AGGCACAG CUGUGCCUU AAUUCAGA 5077 UUCUGAAU CUGAUGA X GAA AAGGCACA UGUGCCUUA AUUCAGAA 5080 GUGUUCUG CUGAUGA X GAA AUUAAGGC GCCUUAAUU CAGAACAC 5081 GGUGUUCU CUGAUGA X GAA AAUUAAGG CCUUAAUUC AGAACACC 5105 CCUCUGCC CUGAUGA X GAA ACGUUCCU AGGAACGUC GGCAGAGG 5116 CCCGUCAG CUGAUGA X GAA AGCCUCUG CAGAGGCUC CUGACGGG 5135 GUUCUCAC CUGAUGA X GAA AUUCUUCG CGAAGAAUU GUGAGAAC 5156 GAAACCCU CUGAUGA X GAA AGUUUCUG CAGAAACUC AGGGUUUC 5162 CCAGCAGA CUGAUGA X GAA ACCCUGAG CUCAGGGUU UCUGCUGG 5163 CCCAGCAG CUGAUGA X GAA AACCCUGA UCAGGGUUU CUGCUGGG 5164 ACCCAGCA CUGAUGA X GAA AAACCCUG CAGGGUUUC UGCUGGGU 5203 AACCCUCA CUGAUGA X GAA ACCUGCCA UGGCAGGUC UGAGGGUU 5211 UGACAGAG CUGAUGA X GAA ACCCUCAG CUGAGGGUU CUCUGUCA 5212 UUGACAGA CUGAUGA X GAA AACCCUCA UGAGGGUUC UCUGUCAA 5214 ACUUGACA CUGAUGA X GAA AGAACCCU AGGGUUCUC UGUCAAGU 5218 CGCCACUU CUGAUGA X GAA ACAGAGAA UUCUCUGUC AAGUGGCG 5229 UGAGCCUU CUGAUGA X GAA ACCGCCAC GUGGCGGUA AAGGCUCA 5236 ACCAGCCU CUGAUGA X GAA AGCCUUUA UAAAGGCUC AGGCUGGU 5247 AGAGGAAG CUGAUGA X GAA ACACCAGC GCUGGUGUU CUUCCUCU 5248 UAGAGGAA CUGAUGA X GAA AACACCAG CUGGUGUUC UUCCUCUA 5250 GAUAGAGG CUGAUGA X GAA AGAACACC GGUGUUCUU CCUCUAUC 5251 AGAUAGAG CUGAUGA X GAA AAGAACAC GUGUUCUUC CUCUAUCU 5254 UGGAGAUA CUGAUGA X GAA AGGAAGAA UUCUUCCUC UAUCUCCA 5256 AGUGGAGA CUGAUGA X GAA AGAGGAAG CUUCCUCUA UCUCCACU 5258 GGAGUGGA CUGAUGA X GAA AUAGAGGA UCCUCUAUC UCCACUCC 5260 CAGGAGUG CUGAUGA X GAA AGAUAGAG CUCUAUCUC CACUCCUG 5265 CCUGACAG CUGAUGA X GAA AGUGGAGA UCUCCACUC CUGUCAGG 5270 GGGGGCCU CUGAUGA X GAA ACAGGAGU ACUCCUGUC AGGCCCCC 5283 AUACUGAG CUGAUGA X GAA ACUUGGGG CCCCAAGUC CUCAGUAU 5286 AAAAUACU CUGAUGA X GAA AGGACUUG CAAGUCCUC AGUAUUUU 5290 AGCUAAAA CUGAUGA X GAA ACUGAGGA UCCUCAGUA UUUUAGCU 5292 AAAGCUAA CUGAUGA X GAA AUACUGAG CUCAGUAUU UUAGCUUU 5293 CAAAGCUA CUGAUGA X GAA AAUACUGA UCAGUAUUU UAGCUUUG 5294 ACAAAGCU CUGAUGA X GAA AAAUACUG CAGUAUUUU AGCUUUGU 5295 CACAAAGC CUGAUGA X GAA AAAAUACU AGUAUUUUA GCUUUGUG 5299 AAGCCACA CUGAUGA X GAA AGCUAAAA UUUUAGCUU UGUGGCUU 5300 GAAGCCAC CUGAUGA X GAA AAGCUAAA UUUAGCUUU GUGGCUUC 5307 CCAUCAGG CUGAUGA X GAA AGCCACAA UUGUGGCUU CCUGAUGG 5308 GCCAUCAG CUGAUGA X GAA AAGCCACA UGUGGCUUC CUGAUGGC 5325 CCAAUUAA CUGAUGA X GAA AUUUUUCU AGAAAAAUC UUAAUUGG 5327 AACCAAUU CUGAUGA X GAA AGAUUUUU AAAAAUCUU AAUUGGUU 5328 CAACCAAU CUGAUGA X GAA AAGAUUUU AAAAUCUUA AUUGGUUG 5331 AACCAACC CUGAUGA X GAA AUUAAGAU AUCUUAAUU GGUUGGUU 5335 AGCAAACC CUGAUGA X GAA ACCAAUUA UAAUUGGUU GGUUUGCU 5339 GGAGAGCA CUGAUGA X GAA ACCAACCA UGGUUGGUU UGCUCUCC 5340 UGGAGAGC CUGAUGA X GAA AACCAACC GGUUGGUUU GCUCUCCA 5344 UAUCUGGA CUGAUGA X GAA AGCAAACC GGUUUGCUC UCCAGAUA 5346 AUUAUCUG CUGAUGA X GAA AGAGCAAA UUUGCUCUC CAGAUAAU 5352 CUAGUGAU CUGAUGA X GAA AUCUGGAG CUCCAGAUA AUCACUAG 5355 UGGCUAGU CUGAUGA X GAA AUUAUCUG CAGAUAAUC ACUAGCCA 5359 AAUCUGGC CUGAUGA X GAA AGUGAUUA UAAUCACUA GCCAGAUU 5367 AAUUUCGA CUGAUGA X GAA AUCUGGCU AGCCAGAUU UCGAAAUU 5368 UAAUUUCG CUGAUGA X GAA AAUCUGGC GCCAGAUUU CGAAAUUA 5369 GUAAUUUC CUGAUGA X GAA AAAUCUGG CCAGAUUUC GAAAUUAC 5375 UAAAAAGU CUGAUGA X GAA AUUUCGAA UUCGAAAUU ACUUUUUA 5376 CUAAAAAG CUGAUGA X GAA AAUUUCGA UCGAAAUUA CUUUUUAG 5379 CGGCUAAA CUGAUGA X GAA AGUAAUUU AAAUUACUU UUUAGCCG 5380 UCGGCUAA CUGAUGA X GAA AAGUAAUU AAUUACUUU UUAGCCGA 5381 CUCGGCUA CUGAUGA X GAA AAAGUAAU AUUACUUUU UAGCCGAG 5382 CCUCGGCU CUGAUGA X GAA AAAAGUAA UUACUUUUU AGCCGAGG 5383 ACCUCGGC CUGAUGA X GAA AAAAAGUA UACUUUUUA GCCGAGGU 5392 GUUAUCAU CUGAUGA X GAA ACCUCGGC GCCGAGGUU AUGAUAAC 5393 UGUUAUCA CUGAUGA X GAA AACCUCGG CCGAGGUUA UGAUAACA 5398 GUAGAUGU CUGAUGA X GAA AUCAUAAC GUUAUGAUA ACAUCUAC 5403 AUACAGUA CUGAUGA X GAA AUGUUAUC GAUAACAUC UACUGUAU 5405 GGAUACAG CUGAUGA X GAA AGAUGUUA UAACAUCUA CUGUAUCC 5410 CUAAAGGA CUGAUGA X GAA ACAGUAGA UCUACUGUA UCCUUUAG 5 12 UUCUAAAG CUGAUGA X GAA AUACAGUA UACUGUAUC CUUUAGAA 5415 AAAUUCUA CUGAUGA X GAA AGGAUACA UGUAUCCUU UAGAAUUU 5416 AAAAUUCU CUGAUGA X GAA AAGGAUAC GUAUCCUUU AGAAUUUU 5417 UAAAAUUC CUGAUGA X GAA AAAGGAUA UAUCCUUUA GAAUUUUA 5422 UAGGUUAA CUGAUGA X GAA AUUCUAAA UUUAGAAUU UUAACCUA 5423 AUAGGUUA CUGAUGA X GAA AAUUCUAA UUAGAAUUU UAACCUAU 5424 UAUAGGUU CUGAUGA X GAA AAAUUCUA UAGAAUUUU AACCUAUA 5425 UUAUAGGU CUGAUGA X GAA AAAAUUCU AGAAUUUUA ACCUAUAA 5430 UAGUUUUA CUGAUGA X GAA AGGUUAAA UUUAACCUA UAAAACUA 5432 CAUAGUUU CUGAUGA X GAA AUAGGUUA UAACCUAUA AAACUAUG 5438 AGUAGACA CUGAUGA X GAA AGUUUUAU AUAAAACUA UGUCUACU 5442 AACCAGUA CUGAUGA X GAA ACAUAGUU AACUAUGUC UACUGGUU 5444 GAAACCAG CUGAUGA X GAA AGACAUAG CUAUGUCUA CUGGUUUC 5450 CAGGCAGA CUGAUGA X GAA ACCAGUAG CUACUGGUU UCUGCCUG 5451 ACAGGCAG CUGAUGA X GAA AACCAGUA UACUGGUUU CUGCCUGU 5452 CACAGGCA CUGAUGA X GAA AAACCAGU ACUGGUUUC UGCCUGUG Where "X" represents stem II region of a HH ribozyme (Hertel et al . , 1992 Nucleic Acids Res . 20 3252) . The length of stem II may be > 2 base-pairs. Table VII: Mouse flk- 1 VEGF Receptor-Hairpin Ribozyme and Substrate Sequences HP Ribozyme Sequence Substrate ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 807 CUGUUUCC AGAA GGAACA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UGUUCCG GAU GGAAACAG 920 ACAUGAUA AGAA GAUAGG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CCUAUCA GUC UAUCAUGU 1002 UUUUCUCC AGAA GAUAGC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GCUAUCU GCC GGAGAAAA 1229 UCUUGAUC AGAA GUCCAC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GUGGACG GAU GAUCAAGA 5 1365 AUAUCAGG AGAA GGGUAA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UUACCCA GCU CCUGAUAU 1556 UCUCACCG AGAA GGGGUG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CACCCCA GAU CGGUGAGA 1629 UUGGCGUA AGAA GUGCAU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AUGCACA GUC UACGCCAA 1687 UCUGUAGG AGAA GGCUUC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GAAGCCU GCU CCUACAGA in 1696 UUGGCCGG AGAA GUAGGA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UCCUACA GAC CCGGCCAA 10 1796 UUCCUUCA AGAA GGGCAU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AUGCCCU GAU UGAAGGAA 1950 GGCUGGGC AGAA GGUUGC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GCAACCU GCU GCCCAGCC 1953 GUUGGCUG AGAA GCAGGU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCUGCU GCC CAGCCAAC 1985 CAGUGCAC AGAA GGGACA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UGUCCCU GUU GUGCACUG 2055 CCCAUGUG AGAA GAUGUU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AACAUCG GUC CACAUGGG 15 2082 UUCUUGCA AGAA GGUGUG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CACACCA GUU UGCAAGAA 2208 UUAUCUUG AGAA GAGCAA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UUGCUCU GCU CAAGAUAA 2252 GGAUGAUG AGAA GUUUGA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UCAAACA GCU CAUCAUCC 2444 UGCGGAUA AGAA GGUUCC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGAACCU GAC UAUCCGCA 2639 GCUUAACG AGAA GUAGGA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UCCUACG GAC CGUUAAGC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UCACGCU GAC UCAGGGAC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CACUGCA GCU CACCUCCU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCUCCU GUU UAAAUGGA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UGGUCCU GUC CCGGCUCC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UGUCCCG GCU CCGCCCCC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CGGCUCC GCC CCCAACUC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AGGUGCU GCU UAGAUUUU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GACCUCA GAC UGCAAGGA cn ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GUGCCCU GCU GUGGUCUC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGACUCU GUC CUCCAAGA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CGAGUCU GUC UACCUUGG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GAGAGCG GUU GGAGCCUG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GCCUGCA GAU GCAUUGUG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AAAGGCG GCC GGCAGGGU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CUUCACA GUC GGGUUACA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CCUUCCG GAC UCUUACGU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UGAUGCA GCU UGCUCCUU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGCUCCU GAC GGGGCCGA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGUUUCU GCU GGGUGGAG 5310 UUUCUGCC AGAA GGAAGC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GCUUCCU GAU GGCAGAAA 5363 AUUUCGAA AGAA GGCUAG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CUAGCCA GAU UUCGAAAU 5453 AGCACACA AGAA GAAACC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGUUUCU GCC UGUGUGCU cn GAA AGUUUGUC GACAAACUA UCUGACCC GAA AUAGUUUG CAAACUAUC UGACCCAU GAA AUGGGUCA UGACCCAUC GGCAGACC GAA AUUGGUCU AGACCAAUA CAAUCCUA GAA AUUGUAUU AAUACAAUC CUAGAUGU GAA AGGAUUGU ACAAUCCUA GAUGUCCA GAA ACAUCUAG CUAGAUGUC CAAAUACG GAA AUUUGGAC GUCCAAAUA CGCCCGCC GAA AGCAGUCU AGACUGCUC CACGGGCA GAA AGUCUGCC GGCAGACUC UUGUCCUC GAA AGAGUCUG CAGACUCUU GUCCUCAA GAA ACAAGAGU ACUCUUGUC CUCAACUG GAA AGGACAAG CUUGUCCUC AACUGCAC GAA AGCUCCGU ACGGAGCUC AAUACGAG GAA AUUGAGCU AGCUCAAUA CGAGGGUG GAA AUUCCAGC GCUGGAAUU ACCCUGGU GAA AAUUCCAG CUGGAAUUA CCCUGGUA GAA ACCAGGGU ACCCUGGUA AAGCAACU GAA AGUUGCUU AAGCAACUA AGAGAGCA GAA AUGCUCUC GAGAGCAUC UAUAAGGC GAA AGAUGCUC GAGCAUCUA UAAGGCAG GAA AUAGAUGC GCAUCUAUA AGGCAGCG GAA AUCCGCUG CAGCGGAUU GACCGGAG GAA AUGGCUCC GGAGCCAUU CCCACAAC GAA AAUGGCUC GAGCCAUUC CCACAACA GAA ACACAUUG CAAUGUGUU CCACAGUG GAA AACACAUU AAUGUGUUC CACAGUGU GAA ACACUGUG CACAGUGUU CUUAAGAU GAA AACACUGU ACAGUGUUC UUAAGAUC GAA AGAACACU AGUGUUCUU AAGAUCAA GAA AAGAACAC GUGUUCUUA AGAUCAAC GAA AUCUUAAG CUUAAGAUC AACAAUGU GAA AGCCCCUU AAGGGGCUC UACACCUG GAA AAGCAGGU ACCUGCUUC AAAACCUC GAA AGGUUUUG CAAAACCUC AGUGACUA GAA AGUCACUG CAGUGACUA CGAGGUCU GAA ACCUCGUA UACGAGGUC UCCAUCAG GAA AGACCUCG CGAGGUCUC CAUCAGUG GAA AUGGAGAC GUCUCCAUC AGUGGCUC GAA AGCCACUG CAGUGGCUC UACGACCU GAA AGAGCCAC GUGGCUCUA CGACCUUA GAA AGGUCGUA UACGACCUU AGACUGUC GAA AAGGUCGU ACGACCUUA GACUGUCA GAA ACAGUCUA UAGACUGUC AAGCUAGA GAA AGCUUGAC GUCAAGCUA GAGGUGUC GAA ACACCUCU AGAGGUGUC CCCGCGCC GAA AGGCGCGG CCGCGCCUC AGAUCACU GAA AUCUGAGG CCUCAGAUC ACUUGGUU GAA AGUGAUCU AGAUCACUU GGUUCAAA GAA ACCAAGUG CACUUGGUU CAAAAACA GAA AACCAAGU ACUUGGUUC AAAAACAA GAA AUUUUGUG CACAAAAUA CAACAAGA GAA AUUCCCGG CCGGGAAUU AUUUUAGG GAA AAUUCCCG CGGGAAUUA UUUUAGGA GAA AUAAUUCC GGAAUUAUU UUAGGACC GAA AAUAAUUC GAAUUAUUU UAGGACCA GAA AAAUAAUU AAUUAUUUU AGGACCAG GAA AAAAUAAU AUUAUUUUA GGACCAGG GAA ACAGCGUG CACGCUGUU UAUUGAAA GAA AACAGCGU ACGCUGUUU AUUGAAAG GAA AAACAGCG CGCUGUUUA UUGAAAGA GAA AUAAACAG CUGUUUAUU GAAAGAGU GAA ACUCUUUC GAAAGAGUC ACAGAGGA GAA ACACCCUC GAGGGUGUC UAUAGGUG GAA AGACACCC GGGUGUCUA UAGGUGCC GAA AUAGACAC GUGUCUAUA GGUGCCGA Where "X" represents stem II region of a HH ribozyme (Hertel et al., 1992 Nucleic Acids Res . 20 3252) . The length of stem II may be ≥ 2 base-pairs. Table IX: Mouse fltl VEGF Receptor-Hairpin Ribozyme and Substrate Sequence P Ribozyme Sequence Substrate ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AUGGUCA GCU GCUGGGAC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GUCAGCU GCU GGGACACC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CACCGCG GUC UUGCCUUA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACGCGCU GCU CGGGUGUC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGUGUCU GCU UCUCACAG oo ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CAGGCCA GAC UCUCUUUC * » ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGAGGCA GCC CACUCAUG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGUCUCU GCC CACGACCG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CCCAUCG GCC UGUGGGAG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GAAGACA GCU CAUCAUCC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AUCCCCU GCC GGGUGACG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UACCCCU GAU GGGCAAAG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UAGGACU GCU GAACUGCG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACUAUCU GAC CCAUCGGC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AUCGGCA GAC CAAUACAA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UACGCCC GCC GAGCCCAG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UGAGACU GCU CCACGGGC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACGGGCA GAC UCUUGUCC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGCAGCG GAU UGACCGGA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UACACCU GUC GCGUGAAG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CGUUCCA GUC UUUCAACA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGAAGCA GCC GGUGCAGG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GAAGACG GUC CUAUCGGC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CCUAUCG GCU GUCCAUGA oo ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AUCGGCU GUC CAUGAAAG n ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GAAGUCU GCU CGCUAUUU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AACCUCA GAU CUACGAAA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UCUAUCC GCU GGGCAGCA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGUGGCU GAC UCUCAGAC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACUCUCA GAC CCCUGGAA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AUCUACA GCU GCCGGGCC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UACAGCU GCC GGGCCUUC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UGUCACA GAU GUGCCGAA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GAUGCCA GCC GAAGGAGA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UGAAACU GUC CUGUGUGG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CACACCU GCU UCAAAACC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CGCCUCA GAU CACUUGGU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GCACGCU GUU UAUUGAAA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AAGCGCA GCC UACCUCAC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UGGAGCU GAU CACGCUCA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UGAAGCG GUC UUCUUCCG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AAAGACA GAC UACCUGUC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGACCCA GAU GAAGUUCC 00 cn ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GUGAACG GCU GCCCUAUG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AACGGCU GCC CUAUGAUG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CCCACCU GCC GGACUGUG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CCUGCCG GAC UGUGGCUG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AAGCUCU GAU GACCGAAC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGCCUCU GAU GGUGAUCG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GAAACCU GUC CAACUACC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UUAUUCU GUC UCAACAAG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGACGCA GCC UUGCAUAU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AAGCCCC GCC UAGACAGU 2 913 GACACUUG AGAA GCUGAC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GUCAGCA GCU CAAGUGUC 2928 GAAGCUGG AGAA GGUGAC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GUCACCA GCU CCAGCUUC 2 934 UUCAGGGA AGAA GGAGCU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AGCUCCA GCU UCCCUGAA 3001 UGGUGAGG AGAA GCUUGG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CCAAGCA GCC CCUCACCA 5 3 022 UGUAGGAA AGAA GGUCUU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AAGACCU GAU UUCCUACA 3033 CACUUGGA AGAA GUAGGA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UCCUACA GUU UCCAAGUG 3064 UUCUGGAG AGAA GAAACU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AGUUUCU GUC CUCCAGAA 3 179 CUCACAUA AGAA GGGUUC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GAACCCU GAU UAUGUGAG 33 57 CUUCAGGC AGAA GCAGAA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UUCUGCA GCC GCCUGAAG - 00 10 3360 UUCCUUCA AGAA GCUGCA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UGCAGCC GCC UGAAGGAA 33 79 GGGUUCUC AGAA GCAUGC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GCAUGCG GAU GAGAACCC 3463 GUUCAGCA AGAA GGGGCC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGCCCCG GUU UGCUGAAC 34 96 UGGCUUGA AGAA GGUCAC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GUGACCU GCU UCAAGCCA 3553 UGUUUCUA AGAA GUAUGG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CCAUACU GAC UAGAAACA 15 3615 AUCUGCAA AGAA GUCCUU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AAGGACG GCU UUGCAGAU 3623 AAAUGUGG AGAA GCAAAG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CUUUGCA GAU CCACAUUU 3650 CUCACAUC AGAA GAGCUU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AAGCUCU GAU GAUGUGAG 3754 UAGUGUCC AGAA GAUAGU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACUAUCA GCU GGACACUA 3772 GGGAGCCC AGAA GAGUGC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GCACUCU GCU GGGCUCCC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UGAAGCG GUU CACCUGGA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACUUUCC GAU CUGCCGAG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CCGAUCU GCC GAGGCCCA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AGGCCCA GCU UCUGCUUC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AGCUUCU GCU UCUCCAGC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UUCUCCA GCU GUGGCCAC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GAGUCCU GCU GUUCUCCA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UCCUGCU GUU CUCCACCC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCCCCA GAC UACAACUC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CCUCCCC GCC CGCCUAAA ° 0°0 ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CCCGCCC GCC UAAAGCUU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CUCACCA GCC CCGACAAC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACAACCA GCC CCUGACAG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CUAUUCC GCU CCACAGGA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGAGCCA GCU GCUUUUCG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GCCAGCU GCU UUUCGUGA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UGUUGCU GUU UUGACUAA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGCGACC GCC CGCCCACC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA ACCGCCC GCC CACCGGCC 4329 AGUCCCAC AGAA GCAGGG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CCCUGCA GCU GUGGGACU 4378 CAGAGCAG AGAA GUGCAU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AUGCACU GAC CUGCUCUG 4383 AGAGACAG AGAA GGUCAG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CUGACCU GCU CUGUCUCU 4388 AUAAGAGA AGAA GAGCAG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CUGCUCU GUC UCUCUUAU 5 4457 CUCCACAG AGAA GACGCA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UGCGUCC GUC CUGUGGAG 4525 CCCGAAAC AGAA GAGGCC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGCCUCC GCU GUUUCGGG 4528 GGGCCCGA AGAA GCGGAG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CUCCGCU GUU UCGGGCCC 4643 AAACAGAC AGAA GAAGAC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GUCUUCU GUU GUCUGUUU 4650 GGAUGGUA AGAA GACAAC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GUUGUCU GUU UACCAUCC 10 4724 ACUAGAGG AGAA GAUGAU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AUCAUCA GUU CCUCUAGU g 4771 AUGCGAAG AGAA GGCCUG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CAGGCCU GAC CUUCGCAU 4785 UCCCCGUG AGAA GUAUGC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GCAUACU GCU CACGGGGA 4809 CUAGGCCA AGAA GGACCA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UGGUCCA GUU UGGCCUAG 4834 UUGAGCCC AGAA GUAGGC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GCCUACU GAU GGGCUCAA 15 4 912 AUAUAUAA AGAA GGAUAA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UUAUCCU GUU UUAUAUAU 5119 UCCUCUCA AGAA GCCUUG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA CAAGGCA GUC UGAGAGGA 5144 UAAAUAUG AGAA GAUACU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA AGUAUCA GCC CAUAUUUA 5287 AGGUAUGA AGAA GAUGAA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA UUCAUCU GUU UCAUACCU 5363 CCCCAAAG AGAA GGCACC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA GGUGCCC GCU CUUUGGGG 5462 CCGGCUCC AGAA GGUGUG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 5478 GUCUGCCC AGAA GUGACC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 5486 UAUUCAUC AGAA GCCCAG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 5500 UCUCCCAA AGAA GCUAUU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 5 5539 CUGGCCCG AGAA GAGAAU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 5564 CACAGGGG AGAA GGUACC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 5597 UCUCAUCA AGAA GAAAAC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 5601 CCAGUCUC AGAA GACAGA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 563 9 GGGCUGCA AGAA GUCUCA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 10 5646 CCACAGUG AGAA GCAGGC ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 5781 CACACUGC AGAA GACAAG ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 5829 CUGUUCUC AGAA GUUUCU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 5842 AAACCUCA AGAA GCUGUU ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 5915 UUAUUAAA AGAA GAAUAA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA 15 6010 AGUCUUUA AGAA GAACCA ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA able X: Homolo ous Hammerhead Riboz m Lowercase letters are used to represent sequence variance between flt-1 and KDR RNA Table XI: 2.5 umol RNA Synthesis Cycle Reagent Phosphoramidites S-Ethyl Tetrazole Acetic Anhydride N-Methyl Imidazole TCA Iodine Acetonitrile

Claims: Claims 1. Nucleic acid molecule which modulates the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor. 2. The nucleic acid of claim 1, wherein said receptor is flt-1, KDR and/or flk-1. 3. The nucleic acid of claim 1 or 2 , wherein said molecule is an enzymatic nucleic acid molecule. 4. The nucleic acid molecule -.of claim 3, wherein, the binding arms of said enzymatic nucleic acid contain sequences complementary to the substrate nucleotide base sequences in any one of Tables II to IX. 5. The nucleic acid molecule of claims 3 or 4, wherein said nucleic acid molecule is in a hammerhead motif . 6. The enzymatic nucleic acid molecule of claim 3 or 4, wherein said nucleic acid molecule is in a hairpin, hepatitis Delta virus, group I intron, VS nucleic acid or RNaseP nucleic acid motif. 7. The enzymatic nucleic acid molecule of any of claims 3 or 4, wherein said ribozyme comprises between 12 and 100 bases complementary to the RNA of said region. 8. The enzymatic nucleic acid of claim 7, wherein said ribozyme comprises between 14 and 24 bases comple¬ mentary to the RNA of said region. 9. Enzymatic nucleic acid molecule consisting essentially of any ribozyme sequence selected from those shown in Tables II to IX. 10. A mammalian cell including a nucleic acid molecule of any of claims 1, 2 or 3. 11. The cell of claim 10, wherein said cell is a human cell. 12. An expression vector comprising nucleic acid encoding the nucleic acid molecule of any of claims 1, 2, 3 or 4, in a manner which allows expression and/or delivery of that RNA molecule within a mammalian cell. 13. The expression vector of claim 12, wherein said nucleic acid is an enzymatic nucleic acid. 14. A mammalian cell including an expression vector of any of claims 12 or 13. 15. The cell of claim 14, wherein said cell is a human cell. 16. A method for treatment of a patient having a condition associated with the level of flt-1, KDR and/or flk-1, wherein the patient, tissue donor or population of corresponding cells is administered a therapeutically effective amount of an enzymatic nucleic acid molecule of claims 1, 2, 3 or . 17. A method for treatment of a condition related to the level of flt-1, KDR and/or flk-1 activity by adminis¬ tering to a patient an expression vector of claim 12. 18. The method of claims 16 or 17, wherein said patient is a human. 19. The nucleic acid of claim 1 or 2, wherein said molecule is an antisense nucleic acid molecule. 20. The nucleic acid molecule of claim 19, wherein, said antisense nucleic acid contain sequences comple¬ mentary to the substrate nucleotide base sequences in any one of Tables II to IX. 21. An expression vector comprising nucleic acid encoding the antisense nucleic acid molecule of any one of claims 19 or 20, in a manner which allows expression and/or delivery of that antisense RNA molecule within a mammalian cell. 22. A mammalian cell including an expression vector of claim 21. 23. The cell of claim 22, wherein said cell is a human cell.

Inventors: ESCOBEDO JAIME, MCSWIGGEN JAMES, PAVCO PAMELA, STINCHCOMB DAN, ESCOBEDO, JAIME, MCSWIGGEN, JAMES, PAVCO, PAMELA, STINCHCOMB, DAN
Applicants: CHIRON CORP, RIBOZYME PHARM INC, CHIRON CORPORATION, RIBOZYME PHARMACEUTICALS, INC.
Application year: 1996
Main classification: C12N15
IPC codes: A61K31, A61K35, A61K38, A61K48, A61P17, C07H21, C12N5, C12N9, C12N15